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ABSTRACT
Cytochrome P-450 (CYP) and inducible nitric oxide synthase (iNOS) are similar heme 
containing enzymes. Cimetidine (CIM) is an H2 antagonist, and since CIM inhibits CYP, it 
may also bind to the heme-iron o f iNOS and reduce NO generation.
Six horses each had three tissue chambers inserted subcutaneous!y on either side o f the 
neck for Trial 1. Trial 2 also used 6  female Thoroughbred horses implanted with at least two 
tissue chambers as in Trial 1. Blood and tissue chamber fluid (TCF) were sampled at -24, 0, 4, 
8 , 12 h and at 1,2, 3, S, and 7 days after carrageenan instillation for Trial 1 a similar schedule 
was used for Trial 2.
Tissue chamber fluid (TCF) interleukin (IL)-1 concentrations were increased following 
NaCl inflamed (NaCl-1), CIM, or aminoguanidine (AG) treatment when compared to non­
inflamed chamber TCF. For IL-6 , NaCl-I and CIM were significantly increased when 
compared to NaCl non-inflamed (-N). There was no significant difference between the area 
under the curve (AUC) of IL-1  or IL-6  in NaCl-I TCF vs. CIM or AG TCF. Cimetidine 
significantly decreased N 03' AUCs in plasma. Aminoguanidine and CIM decreased N 03‘ 
AUCs in TCF in Trials 1 and 2. These results indicate that CIM had an effect on some 
inflammatory indices in this model. Surprising is the inhibition o f N 03' formation by CIM. 
This could be the result o f direct inhibition of iNOS, direct inhibition of CYP, and/or an 
interaction at H2 receptors that have a role in the regulation of iNOS.
For CIM, classical Type II spectra, similar to those previously reported, were obtained 
at concentrations sO.l mM in both rat and equine hepatic microsome preparations. Both 
hexobarbital and AG produced a Type I difference spectra in rat and equine hepatic microsome 
preparations. The interaction o f CIM with a leukocyte preparation resulted in atypical spectra, 
but provided evidence for interaction with a chromophore in TCF. Cimetidine also did not
xi
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affect the conversion o f NO to N 03'  catalyzed by hemoglobin. Western blot analysis, however, 
failed to identify iNOS in the leukocyte preparation.
xii
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CHAPTER 1. LITERATURE REVIEW  
Cimetidine (CIM) is a histamine (HIS) type 2-receptor antagonist commonly employed 
in racehorses to treat, or reduce the incidence of, stress induced gastric ulceration. Cimetidine 
has also been shown to produce several other useful effects. Studies have shown that H2- 
receptor antagonists have anti-tumor, anti-infective, and either pro- or anti-inflammatory 
properties. Cimetidine and similar compounds have been shown to reduce the size of 
melanomas (Goetz, et a l 1990a; Goetz, et al., 1990b; Jenkins, 1991), reduce the severity of 
pulmonary cardiovascular effects in a porcine respiratory distress syndrome model (Byrne, et 
al., 1990), enhance resistance to pneumonia in calves and swine (Canning, 199S; Canning, et 
al., 199S), reduce hyperoxic lung injury in lambs (Hazinski, et al., 1988), and reduce pain 
associated with rheumatoid arthritis (Grabowski, et al., 1996). The cytotoxic antitumor and 
anti-infective activity may be related to their blockade of H2 receptor mediated suppression of 
cytokine generation and macrophage activation. Some of the H^receptor antagonists have also 
been shown to act as free radical scavengers, but this could be due to their binding to the iron- 
heme of cytochrome P-450 (CYP), retarding superoxide anion generation (Hazinski, et al., 
1988).
Inflammatory and immunological stimuli suppress CYP when immune cells secrete 
cytokines. Cytokines are also known to induce nitric oxide synthase (NOS) and it has been 
shown that nitric oxide (NO) inhibits CYP medicated metabolism of xenobiotic substrates. It 
has recently been shown that inhibitors of NOS prevent cytokine-mediated decreases in CYP 
protein (Carlson & Billings, 1996). Also, increased concentrations of NO resulted in decreases 
in CYP proteins.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Inflammation is a fundamentally pathologic process consisting o f a dynamic complex 
of cytologic and chemical reactions which occur in affected blood vessels and adjacent tissues 
in response to an injury or abnormal stimulation caused by a physical, chemical, or biologic 
insult, including: 1) the local reactions and resulting morphologic changes, 2 ) the destruction or 
removal of the injurious material, 3) the responses that lead to repair and healing. The signs of 
inflammation are: rubor (redness); calor (heat or warmth); tumor (swelling); and dolor (pain); a 
fifth sign, functio laesa, meaning inhibited or lost function, is sometimes added. All of the 
signs may be observed in certain instances, but not in others. Acute inflammation is an 
inflammatory process that has a fairly rapid onset, quickly becomes severe, is usually 
manifested for only a few days, may persist for several days or even a few weeks, and could be 
defined as the microcirculatory response to injury. A small number o f cases proceed to develop 
into chronic and self-perpetuating inflammatory conditions (May, et al., 1987). The number of 
known inflammatory mediators continues to grow as research in the area progresses. The 
classical pro-inflammatory mediators are HIS, bradykinin, prostanoids (such as prostaglandin 
E2), leukotrienes, platelet activating factor, NO, cytokines (some are anti-inflammatory), 
endothelin, and oxygen radicals. While this is not a complete list, it serves as a framework for 
which to discuss the inflammatory cascade.
Inflammation starts at the transcription level with the binding o f nuclear factor-icB 
(NF-kB) to the promoter region of certain pro-inflammatory mediator genes such as 
cycloxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), and several cytokines. 
Inhibition of this transcription factor is the mechanism by which glucocorticoids have anti­
inflammatory effects and is why that class o f therapeutic agents has so many different effects 
on the treated patient (Lee & Burckart, 1998). The inflammatory cascade leads to the
2
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infiltration of various leukocytes, such as neutrophils, lymphocytes, and monocytes, into the 
inflammatory site. These infiltrating cells augment the initial production of mediators by 
producing more as they, in turn, are stimulated (Kubes, et al., 1991; Osborn, 1990). Within a 
few hours after the inflammatory insult, macrophages begin to phagocytize the damaged tissues, 
which may lead to increased injury to surrounding tissue. The infiltration of leukocytes results 
in a “walling-off” o f the injured area. This is accomplished by fibrin deposition that can lead to 
adhesions resulting from leukocyte infiltration. The walled>off areas help keep the 
inflammation from spreading, but can also lead to the formation of abscesses (Guyton & Hall,
1996).
Inflammation can also induce the CYP 3A isoform via glucocorticoid dependent and 
independent mechanisms. The effects of lipopolysaccharide (LPS) on CYP are thought to be a 
direct effect on hepatocytes due to high systemic concentrations of various cytokines. This is in 
contrast to other models of inflammation, such as that induced by carrageenan, that produce a 
more local inflammation and do not achieve high systemic cytokine concentrations. In the 
carrageenan model of inflammation, the expression o f CYP 1A1, 2A1, 2B, 2D, 2EI, 3A, and 
4 A are suppressed (Morgan, 1997).
1.1a. Cytokines
Cytokines are an integral part of the complex inflammatory cascade that includes HIS, 
eicosanoids, endothelin, and NO. Pro-inflammatory cytokines are cleared more rapidly from 
inflamed sites than anti-inflammatory cytokines (Groeneveld, et al., 1997). Cytokines appear to 
have a minor role in osteoarthritis, but in inflammatory arthritis, tumor necrosis factor (TNF)-a 
is present in high concentration of the synovial lining. The concentrations of interleukin (IL)-1 
are also elevated in these patients (Mdchiorri, et al., 1998).
3
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Tumor necrosis factor-a. is typically the first cytokine detected following an 
inflammatory insult There are two isoforms of TNF, a  and p. The a  isoform is predominantly 
associated with inflammation and has a molecular weight o f *19 kDa with a >74% amino acid 
homology across species. It can be synthesized by several cell types, but mainly by leukocytes, 
with NF-kB playing an important role in the transcription o f TNF. The molecule forms a 
trimer in order to have biological activity (Myers & Murtaugh, 1995). In bacterial pneumonia, 
TNF levels increase rapidly from 1 to 12 hours (h) post induction in bronchial lavage fluid and 
then rapidly decrease. Lung tissue continued to release TNF for a considerable time period 
after the decrease in lavage fluid (Bergeron, et al., 1998). In bovine mastitis, also an 
inflammatory condition, TN F-a can be detected both in the milk and in the serum of infected 
animals (Myers & Murtaugh, 1995). In race horses with intra-articular chip fractures, 
significant increases in synovial fluid TNF concentrations were observed at 2 and 12 h post 
race with detectable concentrations still present at 26 h (May, 1997). In LPS treated horses, 
TNF serum concentrations increased over the period of I to 2 h post-LPS (Bueno, et al., 1999).
Interleukin-1  is a pro-inflammatory cytokine which can be secreted from almost every 
nucleated cell in the body. This cytokine has a molecular weight o f *30 kDa and is stored in 
the cytoplasm ofthe producing cells. There are two isoforms of IL-1, termed a  and p. There is 
at least 58% amino acid homology between species studied (Lederer & Czuprynski, 1995). 
Equine IL -ip  has >60% amino acid homology with human and murine IL -ip (Horohov, et al., 
1997). The role of IL-1 in the inflammatory cascade is to activate endothelial cells, in 
conjunction with TNF-a, to express cell surface molecules that increase adhesion of circulating 
neutrophils. Interleukin-1 is also responsible for increases in collagenase synthesis and 
proteoglycan degradation, such as that observed in inflammatory arthritis (Lederer & 
Czuprynski, 1995). Interleukin-1 released during the inflammatory process, is believed to be a
4
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major mediator of LPS or TNF-a induced inhibition of hepatic CYP (Kudo & Kawano, 1999; 
Morgan, 1997; Sewer & Morgan, 1997). This is believed to be both through regulation o f CYP 
protein expression and heme pool size (Kudo & Kawano, 1999). It also stimulates the 
production o f NO and prostaglandin (PG) E2 in a concentration dependent manner (Attur, et al., 
1998; Jfirvinen, et al., 1996; Lu & Fisc us, 1999). In the horse, the main isoform produced is 
IL-1 {3 (May, 1997), which produces an increase in leukocyte infiltration following intra- 
articular administration (Simmons, et al., 1999a). In bronchial lavage fluid, IL-1 levels 
persisted for at least 3 days following induction of pneumonia in mice (Bergeron, et al., 1998). 
Production o f this pro-inflammatory cytokine can be inhibited by treatment with the anti­
inflammatory cytokine, IL-11 (Trepicchio, et al., 1996).
Equine IL-6  is a glycosylated polypeptide with a molecular weight of *20 kDa. There 
is *70% amino acid similarity between equine and porcine species (Horohov, et al., 1997). 
Equine chondrocytes and synovial cells produce IL-6  following stimulation with IL-1 (May,
1997). Formation of IL-6  is regulated by several nuclear factors (NF), but the two main factors 
are NF-IL-6  and NF-kB, with production taking place in monocytes and macrophages 
(Richards, et al., 199S). Interleukin-6  levels were detectable early in induced murine 
pneumonia and were below the detectable limit o f the assay by day 3 of the study (Bergeron, et 
al., 1998). Interleukin- 6  kinetics in mouse serum are bi-phasic, with an initial peak at 4 h 
followed by a second, larger peak at 48 h (Bergeron, et al., 1998). This kinetic profile is 
associated with the pharmacodynamics o f IL-6 . Early in inflammation, IL-6  is anti­
inflammatory and chondro-protective, but as inflammation persists, the protective effect is 
inhibited via transforming growth factor (TGF>p induction (van de Loo, et al., 1997) or 
through inhibition of IL-1 and TNF secretion (Richards, et al., 199S). Interleukin-6  has been 
shown to have an inhibitory effect on CYP activity (Monshouwer, et al., 19%). In collagen
5
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induced arthritis, serum IL- 6  concentrations peaked at 24 h post induction and were not 
detectable on day 7. The pro-inflammatory effects o f IL- 6  can be blocked by the administration 
of an IL- 6  receptor antibody (Alonzi, et al., 1998; Takagi, et al., 1998). This cytokine is also 
capable of decreasing NO production following LPS stimulation (Trepicchio, et al., 1996) and 
ameliorates cartilage proteoglycan destruction (van de Loo, et al., 1997). In horses treated with 
IV LPS, IL-6  serum concentrations increased over the period o f 1 to 8  h after administration 
(Bueno, et al., 1999). Glucocorticoids are able to inhibit the expression of IL-6  via NF-kB 
inhibition (Richards, et al., 199S).
1.1.b. Prostagjaadia E»
The eicosanoids are synthesized from arachidonic acid (AA) via the pathway in which 
PGH2 synthase (E.C. 1.14.99.1) catalyzes the first, and rate-limiting, step (Adams, 1995; 
Boothe, 1995; Campbell & Halushka, 1996; Stryer, 1995). This enzyme has two catalytic 
sites, the first being cyclooxygenase (COX) where AA is changed to PGG2. Cyclooxygenase 
catalyzes the formation of a cyclopentane ring and the addition of four O atoms via two 
molecules o f O2. The second site is for hydroperoxidase which converts PGG2 to PGH2 via a 
two electron reduction o f the 15-hydroperoxy group to a 15-hydroxyl group. Cyclooxygenases 
are located in all cells except mature red blood cells. While all tissues have the capacity to 
produce cyclooxygenase end products (PG and leukotrienes), the concentration varies with the 
type and amount o f the individual isomers.
There are two forms of COX. The constitutive isoform, known as COX-1, has clear 
physiological functions, such as the production of prostacyclin which may have a role in the 
cytoprotection of the gastric mucosa (Vane, 1996), although this concept has been disputed by 
the development of separate COX-1 or COX-2 gene deficient, or “knockout”, mice 
(Langenbach, et al., 1995; Morham, et al., 1995). Cyclooxygenase-1 expression appears to be
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regulated only developmentally (DeWitt, et al., 1996). The second type is an inducible form, 
called COX-2 (Xie, et al., 1991; Xie, et al., 1992). It is induced by an array of stimuli, such as 
LPS, growth factors, tumor promoters, and cytokines (Crofford, et al., 1994; DeWitt, et al., 
1996). Data suggest that the de novo synthesis o f COX-2 in synovial tissue from rheumatoid 
arthritis patients is up-regulated by inflammatory mediators and is suppressed by 
corticosteroids and glucocorticoids (Adams, 1995; Campbell & Halushka, 1996; Crofford, et 
al., 1994).
Ovine PGH2 synthase-1 is an endoplasmic reticulum membrane bound glycoprotein 
(Wilborn, et al., 1995) with a relative subunit molecular mass of *70 kDa. The asymmetric 
unit contains two identical monomers related by a non-crystallographic two-fold axis of 
symmetry. The two monomers exhibit extensive contacts, in agreement with the proposed 
dimeric structure of the detergent-solubilized protein. The dimer is ellipsoidal in shape. 
Residues 34-72 are very similar to that of epidermal growth factor. The next region (residues 
73-116) consists of four right-handed spiral of a-helices. These helices are highly amphipathic 
and create a novel motif for insertion of the enzyme into the lipid bilayer (Garavito, et al., 
1995; Picot, et al., 1994). The membrane-binding motif appears not only to anchor the enzyme 
to the cellular membrane but also offers a direct path from the membrane to the COX active 
site, avoiding solvation and desolvation o f AA into the membrane.
The catalytic domain is a globular structure containing the COX and peroxidase active 
sites. It is comprised of two distinct, but intertwined, lobes of the peptide chain. The larger 
lobe is built up around a “V”-shaped structure formed by two helices which grip a third helix 
like a pair o f tweezers. Four other helices and their intervening loops pack around this “V*- 
shaped structure o f helices to complete the large lobe. The smaller lobe o f the catalytic domain
7
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is created by six different helices which form a bundle with their axes being roughly parallel to 
each other (Garavho, et al., 1995; Picot, eta l., 1994).
The COX-1 active she consists of a long, narrow channel extending from the outer 
surface of the membrane-binding region to the center of the monomer. Tyrosine 385 is found at 
the apex of this channel (Garavho, et al., 1995; Picot, et al., 1994). Serine 530, which is the 
site of acetylation (and inhibition) by aspirin (Loll, et al., 1995), lies along the wall o f the 
channel just below Tyr 385 at a point where the acetylation o f Ser 530 blocks access to the 
upper part of the channel (Loll, et al., 1995). Glutamine 524 is located near Arg 120 and these 
two residues may form a salt bridge; Arg 120 and Glu 524 are the only polar residues in this 
otherwise hydrophobic channel (Picot, et al., 1994).
The COX-1 active crater consists of the upper portion of the channel near Tyr 385 as 
deduced from the locations of Ser 530 and 5-flurbiprofen (a potent inhibitor of COX-1). If Tyr 
385 is replaced by Phe, the activity of COX-1 is abolished. Due to the interaction o f the 
guanidinium group of Arg 120, flurbiprofen sterospecifically binds to COX-1 and is 
hypostulated to do so for ketoprofra and carprofra (Picot, et al., 1994).
The COX-2 isoform is a relatively large dimer (=76 kDa). Cyclooxygenase-2 is also a 
membrane bound enzyme. The overall structure of ovine COX-1 and human COX-2 are very 
similar, which was not unusual given that the amino acid sequences of the two enzymes are 
67% identical. The only two residues not conserved (using the ovine COX-1 numbering 
system) are lie 523 and His 519, which are Val and Arg, respectively, in COX-2 (Browner, 
1996). A transcription factor binding region has been identified in the promoter region o f the 
COX-2 gene and is believed to be NF-IL-6  (Sirois & Richards, 1993). The cytokines IL-1, 
TNF-a, TGF-P, and IL-6  have the capability to induce COX-2 mRNA expression (Chen, et al., 
1999; Geng, et al., 1995).
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Two important facts concerning the COX isoforms: I) the NSAID binding site, which 
is contained within the catalytic domain, is structurally conserved between the two isozymes 
and 2) the X-ray crystal structures of COX-2 showed alternative conformations at the NSAID 
binding site, as well as significant movements of the membrane binding and catalytic domains. 
This appears to indicate that the substrate passes directly from the COX active site to the 
peroxidase active site without having to exit the catalytic domain (Browner, 1996). The 
existence of two isoforms at the aspirin-acetylation site may be pharmacologically significant: 
aspirin acetylation inactivates COX-1, but aspirin-acetylated COX-2 is still capable of 
oxygenating AA, producing 15-hydroxy-eicosatetraenoic acid instead of PGH2 (Loll, et al., 
1995).
Measurements of murine COX activity with varying AA concentrations established that 
the Km values of COX-1 and COX-2 for this substrate were essentially the same: 3.0 and 2.5 
pM, respectively (Meade, et al., 1993). Human COX-1 and COX-2, however, appear to have 
different enzyme kinetics. Purified COX-1 had a specific activity in an O^uptake assay of 18.8 
pmol of O^/min/mg protein, with a Km for AA of 13.8 pM and a corresponding of 1519 
nmol of O^nmol of protein. Purified COX-2, on the other hand, had a specific activity in the 
0 2 assay of 12.2 pmol of Oj/min/mg protein, a Kn for AA of 8.7 pM , and a V—. of 1088 nmol 
o f 0 2/nmoI of protein (Gierse, et al., 1995).
In inflammation, the prostaglandins are synthesized as a  result of various cytokines 
signaling COX-2 transcription. The role of PGE2 in inflammation is the potentiation of edema 
formation via its vasodilatory effects (Williams & Peck, 1977). Prostaglandin E2, the main 
prostaglandin synthesized during inflammation, is formed via COX mediated catalysis and can 
trigger suppression of transcription of another enzyme in the inflammatory cascade, iNOS. In 
various models of inflammation, the effect of PGE2 on inflammation appears to be time
9
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dependent in that if present prior to induction o f inflammation, iNOS activity is suppressed, but 
when administered after inflammation iNOS is not suppressed (Schwacha, et al., 1998). The 
effects of PGE2 on NO production are not clear. When concentrations o f pM of PGE2 or 
iloprost are added to LPS stimulated macrophages, NO production is significantly suppressed 
(Marotta, et al., 1992), but it has been reported to have no effect on NO production when using 
a cytokine-induced model of inflammation (J&rvinen, et al., 1996). The cytokine TNF-a can 
also be inhibited by PGE2, potentially decreasing the amount of NO produced during 
inflammation (Milano, et al., 1995). The COX-2 enzyme can be induced, however, by NO 
(Salvemini, 1997) and TNF-a (Chen, et al., 1999). Current research suggests that the effects 
of various iNOS inhibitors on COX isozymes are not direct effects, but are a result of the 
inhibition o f NO effecting COX-2 induction and production (Salvemini, 1997; Salvemini & 
Masferrer, 1996). Cyclooxygenase-2 can also be inhibited at the transcriptional level by 
corticoids and glucocorticoids, such as cortisol, dexamethasone, and prednisolone (Crofford, et 
al., 1994; Koehler, eta l., 1990; Newman, et al., 1994).
l.l.c . Histamine
Histamine is an endogenous mediator released during allergy and inflammation. It has 
a role as a primary neuromodulator, and regulates the formation of many pro-inflamm atory 
mediators (Auer, et al., 1991; Izzo, et al., 1998; Rezai, et al., 1990; Vannier, et al., 1991). 
The receptors that it stimulates are classified into three distinct types: Hi, H2, & H3. The Hi 
receptors are found in a wide variety of mammalian tissues such as smooth muscle, endothelial 
cells, heart, central nervous system, and lymphocytes (Hill, et al., 1997). In the CNS they are 
located post-synaptically. Histamine type 2 receptors are located in gastric parietal cells 
(Cross, 1977; Cross, 1978), vascular smooth muscle, suppressor T-cells, neutrophils, 
lymphocytes, blood vessels lining the synovial space, CNS, and the heart They are also located
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post-synaptically (Grennan, et al., 1975; Hill, et al., 1997; Mannaioni, et al., 1988). The HIS 
stimulation of parietal cells in the horse is attributed to H2-receptors and is responsive to 
treatment with H2-receptor antagonists (Kitchen, et al., 1998). Histamine type 2 receptors are 
also associated with relaxation of smooth muscle (Toda, 1987), but this may also be associated 
with Hi and H3 receptors (Beyak & Vanner, 1995). Histamine type 3 receptors are found 
mainly in the CNS, but have been identified in peripheral tissues such as the small intestine 
(Izzo, et al., 1998) and on brain mast cells (Rozniecki, et al., 1999). They can be located pre- 
synaptically where they regulate the release of HIS from nerve endings (Hill, et al., 1997) and 
mast cell activation (Rozniecki, et al., 1999).
All three classes of HIS receptors are associated with Ca** channels. The structure of 
H2 receptors has been described at the molecular level. There are species differences, but the 
residues associated with the active site are highly conserved (Black, 1993). Gantz and 
coworkers (1992) have reported that for HIS to bind to the H2-receptor, Asp 98 is essential and 
that Asp 186 provides selectivity of H2 agonists and antagonists. Histamine is metabolized by 
diamine oxidase. This enzyme is located throughout the gastrointestinal tract and is inhibited 
by aminoguanidine (AG), a known inhibitor of iNOS (Bieganski, et al., 1983).
The physiological role of HIS is very diverse. It can bind to H2 receptors and 
suppresses human cytolytic T cell function in lymphocytes (Khan, et al., 1989). Histamine 
stimulates the adherence of neutrophils and eosinophils to vascular endothelium (Foster & 
Cunningham, 1998; Watanabe, et al., 1991). Along with its role as a pro-inflammatory 
mediator, these results suggests a very active role for HIS in inflammation. In various models 
of inflammation, HIS concentrations in inflammatory exudate peak at *1 h after stimulation 
(Capasso, et al., 1975; Di Rosa, et al., 1971). It is of note that HIS concentrations are greater 
in the synovial fluid of osteoarthritic patients than in those with rheumatoid arthritis (Renoux, et
11
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al., 1996). Histamine plays an important role in the regulation of various cytokines associated 
with inflammation. Histamine alters the expression of IL-6  receptors on various cell types by 
decreasing the expression o f this cytokine receptor with a mechanism hypothesized to be linked 
to H2-receptors (Mer&ey, et al., 1991), but it apparently does not alter IL- 6  synthesis directly 
(Vannier & Dinarello, 1994). Histamine can alter IL-6  synthesis following stimulation by IL- 
1P and this synthesis is inhibited by CIM and ranitidine (RAN) via an H2-receptor mechanism 
(Vannier & Dinarello, 1994). Nitric oxide, also an important mediator in inflammation, has its 
synthesis upregulated by HIS through both Hi (Kelm, et al., 1993) and H2 mechanisms while 
H3-receptor agonists reduce this synthesis (Mannaioni, et al., 1997). The lack of anti­
inflammatory effect (edema formation) of H (-antagonists in carrageenan or turpentine induced 
models o f inflammation indicates that Hi-receptors may only have a role in the early phase (0  - 
90 min) o f inflammation (Di Rosa, et al., 1971). Histamine causes the activation o f both NOS 
and COX in the conjunctiva of the eye and is associated with the inflammation observed in 
allergic conjunctivitis (Meijer, et al., 1996). Histamine type 3 receptor agonists also affect 
CNS vascular permeability by inhibiting protein leakage into the CNS, which can be reversed 
by H3-receptor antagonists (McLeod, et al., 1998).
l.l.d . N itric Oxide
Nitric oxide has many physiological and pathophysiological functions. It is associated 
with the regulation of essential vasodilatory tone, inhibition of platelet aggregation and 
adhesion, increased cytotoxicity of macrophages against tumor cells and bacteria, and inhibition 
of CYP. It also acts as a neurotransmitter in both the central and peripheral nervous systems 
(Feldman, et al., 1993; Fukuto & Chaudhuri, 1995; Guyton & Hall, 1996; Veihelmann, et al., 
1997; Zhang & Snyder, 1995). It is the smallest, lightest, and first gas to be identified as a 
biological messenger (Culotta & Koshland, 1992; Nathan, 1992).
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The over-production of NO in inflammation alters the physiologic function of inflamed 
tissues on which physiologic concentrations of NO have an effect (Las kin, et al., 1994). This is 
due to alterations in blood flow resulting from vasodilation, leading to hypotension and 
increased leukocyte infiltration (Las kin, et al., 1994; Lu & Fisc us, 1999). However, it should 
be noted that NO has been shown to reduce leukocyte adhesion, even with the increase in 
leukocyte infiltration associated with inflammation (Granger & Kubes, 1996; Kubes, et al., 
1991).
The inflammation induced by pro-inflammatory cytokines can be inhibited by 
overproduction of NO (Bauer, et al., 1997). The anti-inflammatory cytokine IL-11 has been 
shown to reduce LPS-induced NO production by at least 50% (Trepicchio, et al., 1996). 
Addition of L-Arg into an inflammatory site exacerbates the condition (Laskin, et al., 1994). It 
has been reported that there is involvement of a constitutive NOS (cNOS; probably eNOS) very 
early in the inflammatory process (within the first 1 to 3 h) with iNOS becoming induced 
resulting in increased NO output over the next 3 to 24 h, depending on the species. This may 
not be the case for all diseases. In a rat bile duct ligation model for cirrhosis, eNOS mRNA 
(not iNOS) and NO*' where significantly increased (Liu, et al., 1999). Increases in NO 
production are believed to up-regulate COX-1 and COX-2 and thus increase PGE2 production 
(Salvemini, et al., 1996b) and do not appear to require IL-6  (van de Loo, et al., 1996). Others 
have suggested that NO is a potent inhibitor of both COX and 12-lipoxygenase, but that the NO 
metabolite peroxynitrite (ONOO") does not inhibit either (Fujimoto, et al., 1998). This 
inhibitory mechanism does not appear to operate via binding to the iron-heme of COX 
(Salvemini, 1997). While the mechanism is unknown, exposure of macrophages to O3 has 
resulted in detectable iNOS protein (Pendino, et al., 1993). Synovial fluid concentrations of 
N 03’ (a metabolite o f NO) in rheumatoid arthritis patients where higher than the corresponding
13
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plasma samples, suggesting that NO is involved in this disease (Grabowski, et al., 1996). But 
in horses, intra-articular administration of IL-10 did not result in a significant increase in iNOS 
activity (Simmons, et al., 1999a). Nitric oxide also inhibits the formation o f HIS (Mannaioni, 
et al., 1997). This small molecule has been demonstrated to increase the formation of 
metalloproteinase, an enzyme associated with inflammation (Trachtman, et al., 1996a).
In horses with small intestinal strangulation, a significant increase in mtrotyrosine 
staining, an indication of NO production, was observed in intestinal mucosal leukocytes (Mirza, 
et al., 1999a). In horses with naturally acquired strangulating large-colon volvulus, a 
significant increase in plasma and abdominal fluid NO}' was observed compared to normal 
animals (Mirza, et al., 1999b). It has been noted that platelet activating factor suppresses 
eNOS activity in the intestine which leads to the destruction of the mucosal barrier. This leads 
to the conclusion that below some concentrations, NO is protective in the intestine, but at 
concentrations above this point it is cytotoxic in the GI tract (Hsueh, et al., 1997). The 
bacterium, Helicobacter pylori, associated with gastric ulcers, has been demonstrated to induce 
iNOS mRNA and associated NO production (Hahm, et al., 1997; Tsuji, et al., 1996; Wilson, et 
al., 1996). In horses, N 03‘ concentrations in the urine decreased at 4, 20, and 24 h after LPS 
administrations when compared to pre-treatment values (Bueno, et al., 1999). Nitric oxide has 
also been identified as a mediator in induced laminitis. Infusion o f L-Arg increased indicators 
of pain in lammitic animals as did treatment with NO donors (Hinckley, et al., 1996).
I .l.e  M odels o f iaflammatioa
Several different models o f inflammation have been developed. Each has its own 
benefits, drawbacks, and assumptions. The three basic types currently in use are irritant, 
immunological, and mechanical. Each model investigates different segments of the 
inflammation cascade to provide information about the physiology and pathophysiology of the
14
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disease process. Endogenous mediators of the inflammatory cascade, such as cytokines, can 
also be used to directly induce certain types o f inflammation, such as that associated with 
bacterial infections (Persson, et al., 1996).
The first model involves the use of zymosan as an irritant Inflammation is induced by 
placing a zymosan solution into the location to be inflamed, such as a jo in t Zymosan is a cell 
wall product derived from the yeast Saccharomyces cerevisiae (Cuzzocrea, et al., 1997; van de 
Loo, et al., 1998). This agent activates the complement cascade leading to classical indications 
of inflammation. Elevated levels o f corticosterone, N 02", prostaglandins, TNF-a, IL-1, and IL- 
6  can be found in inflamed areas following the local administration of zymosan (Ridger, et al., 
1997; van de Loo, et al., 1997; van de Loo, et al., 1998) along with the influx o f neutrophils 
into the inflamed area (Boughton-Smith & Ghelani, 199S). The inflammation induced by 
zymosan is typically described as acute and local with noticeable edema formation (Ridger, et 
al., 1997) and can be exacerbated by the addition o f L-Arg (Cuzzocrea, et al., 1997).
Carrageenan has been widely used as an agent for the induction of inflammation. It is a 
sulphated polysaccharide galactan irritant derived from an extract of seaweed. Carrageenan 
stimulates the inflammatory cascade by simultaneously initiating leukocyte infiltration, HIS 
production, IL-l and TNF-a formation (Capasso, et al., 1975; Salvemini, et al., 1996b), and 
increase protein concentrations at the site of inflammation (Sedgwick, et al., 1986). These are 
local events not reflected in the systemic circulation when carrageenan is used as the 
inflammatory stimulant (Higgins & Lees, 1984). It is of note that the anti-inflammatory 
cytokine, IL-10, was not detected in rats following carrageenan-induced inflammation (Ianaro, 
et al., 1995). The inflammatory cascade is initiated upon injection of a £2% solution. Within 4 
h following instillation into the paw of rats, iNOS mRNA is expressed, NO metabolites (NO^, 
N 03', and ONOO) are detected, and edema begins to form (Salvemini, et al., 1996a;
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Salvemini, et al., 1996b). The edema associated with carrageenan-induced inflammation is bi- 
phasic, with eNOS responsible for the initial phase and iNOS having a significant role in the 
extended phase (Salvemini, et al., 1996b). The L-Arg/NO pathway is of primary importance in 
this model o f inflammation (Cuzzocrea, et al., 1998). In horses, three models have been used to 
evaluate the local inflammatory effects of carrageenan. The first involves the implantation of 
carrageenan soaked sponges under the skin. This induces an immediate and pronounced 
inflammatory response and can be used to evaluate various types of anti-inflammatory 
compounds (Higgins & Lees, 1983; Higgins, et al., 1987a; Lees & Higgins, 1986). 
Subcutaneous tissue cages have also been used in horses. One model used polypropylene 
practice golf balls implanted in the neck (Higgins, et al., 1984b) and then instilled with 
carrageenan. The advantages and disadvantages of these models have been discussed (Higgins, 
et al., 1987b), but a brief review is needed here. First, these are models and as such may not 
represent clinical disease. Their purpose is to study some components) of inflammation or 
specific effects of antiinflammatory agents. Next, these are acute inflammatory lesions o f the 
neck and are not anatomically or physiologically identical to lesions seen in other soft tissues, or 
in the synovial space. These models do allow for time sequence sampling of an inflamed lesion 
and analysis of certain inflammatory mediators, but the areas are volume limited and
sample collection could alter the values of the inflammatory mediators.
A third model also uses subcutaneously implanted tissue chambers, but not of the golf 
ball variety. This model uses milled Delrin® thermoplastic covered with silicone rubber to form 
a cup into which interstitial fluid collects and into which test substances such as bacteria, 
carrageenan, or therapeutic agents can be instilled (Beadle, et al., 1989; Clarke, 1989; Clarke, 
et al., 1989a; Clarke, et al., 1989b; Guthrie, et al., 1996). This model allows for longer use of
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the chambers with less chance of bacterial contamination during sampling (Guthrie, et al.,
1996).
Turpentine can also be used to induce an inflammatory response. The mechanism of 
action is similar to carrageenan in that it acts as an irritant on the surrounding soft tissues 
following administration (Turnbull A  Rivier, 1996). It is interesting that while a localized 
inflammation is developed with this model, systemic IL-6  concentrations increase markedly 
after each turpentine injection (Turnbull A  Rivier, 1996).
L ipopolysaccharide is a cell wall component o f Gram(-) bacteria, such as Escherichia 
coli, as is the peptidoglycan polysaccharide (PG/PS) of group A Streptococcal bacteria. Both 
o f these agents can be injected into various species to induce inflammation (Fuseler, et al.,
1997). In rats, the PG/PS model induces a peak inflammatory response at *4 days and returns 
to baseline values by day 10 post-inflammation. Upon injection into the synovial space, this 
model causes a marked influx of neutrophils. The cytokines TNF-a, IL-1, and IL-6 , early 
mediators of equine endotoxic shock (Horohov, et al., 1997), rapidly increased in the systemic 
circulation within the first 12 h, but had returned to baseline by day 2. Serum N 03‘ and N(V 
kinetics were similar to those of IL-1 A  IL-6 , but were detectable in serum until day 7 (Fuseler, 
et al., 1997). This model has also been shown to increase COX expression in synovial tissue 
culture from humans and rats and could be inhibited by glucocorticoids (Sano, et al., 1992). 
The presence of LPS in hepatocyte cell culture increased the production o f NO*\ but this 
production was independent of HIS stimulation in LPS or INF-y free culture (Curran, et al.,
1989). Leukocyte infiltration and N 02~ accumulation increased in parallel in the rat after LPS 
exposure, with TNF-a peaking and returning to baseline in < 6  h (Kohn A  Rung, 1995). The 
production of NO can be enhanced in the LPS model by co-administration of interferon (IFN)-y 
(Pendino, et al., 1993).
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Synovitis is inflammation of the synovial membrane and is generally associated with a 
joint It is also a primary indicator of the presence o f osteoarthritis in the horse. Histamine 
release begins with the initial insult to the joint, thus starting the inflammatory cascade leading 
to the production o f IL-1 and PGE2. This occurs both before and after the infiltration of 
neutrophils and macrophages due to the mechanical disruption of the blood-synovial barrier 
(Palmer & Bertooe, 1994). This eventually leads to the degradation of the cartilage matrix 
(Todhunter & Lust, 1990). Part of the joint deterioration may not be due to inflammatory 
mediators, but to the high intra-articular pressures generated during the disease process (Strand, 
etal., 1998).
A model has recently been developed to duplicate the osteoarthritis/synovitis in the 
horse. Synovitis is induced by transection of the lateral collateral and lateral collateral 
sesamoidean ligaments to induce instability leading to inflammation in the metacarpophalangeal 
joint of the horse. The progression of disease and post-mortem findings are extremely close to 
the actual disease in this species at 8  weeks following induction (Simmons, et al., 1999b). The 
model is similar to the anterior cruciate ligament transection model used in dogs (Fernandes, et 
al., 1995; Pond & Nuki, 1973). This model has been used to evaluate the gait of affected dogs 
(DeCamp, et al., 1996) and as a tool to test the efficacy o f NSAIDs (Fernandes, et al., 1995). 
Synovitis in horses can also be induced by using an irritant to inflame the synovial membrane. 
Carrageenan induces a consistent response in horses following instillation into the equine 
synovial space (Owens, et al., 1996) and models an acute synovitis when compared to the work 
done by Simmons, et al. (1999). Induction of synovitis in horses has also been accomplished 
by instilling polyvinyl alcohol foam particles into the synovial space (Comelissen, et al., 1998). 
This particular model has a serious fault in that it induces a systemic elevation of TNF-a that 
corresponds to the induction of inflammation and lasts for several days. All of these models are
18
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
important in the evaluation of anti-inflammatory drugs in horses since more anti-inflammatory 
agents are prescribed to the horse than any other domestic animal (Higgins, et al., 1984a).
1.2. Histamine type 2-receptor antagonists
Cimetidine and other antagonists have been used for many years to control gastric acid 
secretion in man and in domestic species. They are capable of reducing the damage resulting 
from iscbemia-reperfusion injury due to acid excretion (Nalcamoto, et al., 1998) and also have 
antinociceptive and analgesic properties (Hough, et al., 1997). The H2-receptor antagonists are 
reported to improve the function o f the immune system in immunosuppressed subjects 
(Anderson, et al., 1985; Canning, et al., 1995; Emau, et al., 1984; White & Ballow, 1985). 
Cimetidine has also been shown to be effective in the treatment o f melanomas in horses (Goetz, 
et al., 1990a; Goetz, et al., 1990b; Jenkins, 1991), and Kaposi’s sarcoma and colorectal 
carcinoma in humans (Kelly, et al., 1999; Vannier & Dinarello, 1994). The mechanism of 
action of CIM, and possibly other Hr-antagonists in bacterial infections and cancer therapy is 
reported to be the reversal of T-cell-mediated immunesuppression and subsequent enhancement 
o f natural killer cell activity (Jenkins, 1991; Ogden & Hill, 1980; White & Ballow, 1985). 
More specifically, CIM has been demonstrated to augment mitogen-induced blastogenesis in 
normal human lymphocytes to a level approximately equal to that o f the immunostimulant 
levamisole (Gifford & Schmidtke, 1979). Upon treatment with H2-receptor antagonists, IL-2 
production in lymphocytes is increased (Gifford & Tilberg, 1987). Histamine has been shown 
to induce suppression of human lymphocytes by inhibiting their ability to proliferate. Rezai and 
coworkers (1990) have suggested that this change in immune function is due to ^antagonist 
reversal of the inhibition o f IL-2 gene expression caused by HIS. Interleukin-2 increases the 
expression o f H^receptors on lymphocytes and the addition of CIM decreases the cytotoxic 
effect of EL-2 (Shibata, et al., 1992). The presence of an H rreceptor antagonist does not
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activate lymphocytes; the therapeutic regimen simply keeps the cells from being suppressed. 
Canning’s group (Canning, 1995; Canning, et al., 1995) has reported that several H r 
antagonists have activity against induced bronchopneumonia in cattle and swine that is not 
antibacterial in nature. An explanation may be found in the results reported by Hirasawa, et al. 
(1991), in which a carrageenan model of inflammation was used in rats. They reported that 
when H2-receptor antagonists were administered after induction of inflammation, neutrophil 
numbers increased at the site of inflammation, but did not increase following Hi-receptor 
antagonist treatment. In a model of HIS induced edema, Hi-antagonists decreased edema 
formation and Hz-antagonists did not However, when NO was added (generated from acidified 
NaN02, nitroprusside, or hydroxylamine) to the model, CIM decreased the extent of edema 
formation (Oyanagui & Sato, 1993). Similar results were reported by Hirasawa’s group 
(1987) in which CIM blocked the inhibitory action o f indomethacin on leukocyte accumulation 
but had no effect on edema formation. Cimetidine, but not RAN, has also been shown to reduce 
basal cGMP, the secondary messenger involved in NO signaling, levels in culture (Schroder & 
Schror, 1990).
The H2 antagonists have other effects on the inflammatory process. Several 
compounds have shown the capability to inhibit the production of pro-IL-la via Hrreceptors 
(Tasaka, et al., 1993). Histamine increases IL -ip  mRNA levels via Hrreceptors. Thus 
treatment with an Hr receptor antagonist would decrease IL-lp concentrations (Vannier & 
Dinarello, 1993). This is the same mechanism reported for the regulation of granulocyte- 
macrophage colony-stimulating factor (GM-CSF) and IL-6  in that HIS stimulates production of 
these cytokines and the H2-antagonists decrease their concentrations (Mor, et al., 1995). 
Several Hrreceptor antagonists have been demonstrated to dramatically reduce HIS and 
carrageenan-induced edema in the rat with CIM being the most potent o f those tested with Hr
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receptor antagonists having comparably little or no effect (Al-Haboubi & Zeitlin, 1979; Al- 
Haboubi & Zeitlin, 1982; Al-Haboubi & Zeitlin, 1983; Ezeamuzie & Umezurike, 1989; 
Kaneta, et al., 1993). These results also indicated that part o f the reduction in edema formation 
could not be attributed to an Hrreceptor mechanism (Ezeamuzie A  Umezurike, 1989). These 
compounds have also suppressed edema formation associated with thermal injury and burns 
(Brimblecombe, et al., 1977). Cimetidine treatment also appears to decrease the vascular 
permeability associated with carrageenan inflammation in the guinea pig (Woodward, et al., 
1982). Following substance P instillation to induce joint inflammation in rats, production of 
HIS is initiated and edema formation ensues. In this model CIM decreased edema formation by 
50%, a level similar to that following Hi antagonist treatment (Lam & Ferrell, 1990).
A possible mechanism for the Hrantagonists activity against tumor cells and bacterial 
infections is alteration in oxygen free radical (Of-) production. Cimetidine and RAN have 
shown activity in several different models associated with O2 • tissue damage (Byrne, et al., 
1990; Hazinski, et al., 1988; Tanaka, et al., 1991). In the study reported by Byrne, et al. 
(1990), CIM and RAN showed improvement of the pulmonary microvascular permeability 
injury produced by a systemic Pseudomonas aeruginosa infection in swine. All animals were 
treated with a combination o f ibuprofen, diphenhydramine, and CIM or RAN. The authors 
stated that since the only variable between the two treatment groups was the antagonist used, 
the mechanism by which the infection was cleared must be solely due to H2 receptor blockade. 
The authors could show no significant difference between the two treatment groups ability to 
scavenge (V-.
Another group has used endotoxin and 0 2 to induce pulmonary injury in lambs 
(Hazinski, et al., 1988). After inducing the lung injury, CIM or RAN was administered to 
prevent the resulting hyperoxia. Cimetidine, but not RAN, decreased respiratory failure and
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pulmonary edema in treated lambs. The mechanism hypothesized an increase in pulmonary 
CYP activity observed with this model o f lung injury. Since CIM binds to the heme portion of 
CYP, it inhibits the formation o f O2'*. The possibility exists, since only 0 2- was monitored in 
this study, that the decrease in 0 2- formation could have been due to the reaction o f NO and 0 2‘ 
• to form ONOO\ Large amounts o f NO would have been formed by iNOS due to induction of 
the enzyme by endotoxin (Fukuto & Chaudhuri, 1995). This scenario accounts for CIM’s 
effectiveness, but does not explain RAN’s failure.
In the case of severe burns, CIM is reported to increase survival rate. Tanaka and 
coworkers (1991) found that CIM suppressed post-burn capillary permeability and minimized 
fluid loss in the burned tissue, both of which normally increase after this type o f injury. The 
mechanism of this therapeutic approach was originally thought to be Hrreceptor mediated. 
But, since RAN showed no effect, it was then hypothesized to occur via hydroxyl radical 
scavenging. Hydroxyl radicals are produced by the burned skin and increase vascular 
permeability, and it was suggested that CIM removed these radicals and decreased water loss 
(Tanaka, et al., 1991). Another possible theory could be that the vascular system underlying 
the burned tissue could be traumatized to such an extent that cytokines, such as IL-2 and TNF- 
oc, could induce iNOS and cause an increase in vascular permeability with CIM inhibiting 
iNOS, suppressing NO formation, and restoring vascular tone. Again, this provides a 
mechanism for one of the Hrantagonists, but does not account for the inactivity of another. 
Owen, et al., (1980) have suggested that CIM reduces vascular permeability in a HIS model of 
acute inflammation via an unexplainable mechanism not associated with Hi or H2 receptors.
The pharmacology of CIM (Tagamet®; N"-cyano-N-methyl-N'-[2-[(5-methyl-imidazol-
4-yl)methylthio]ethyl]guanidine; Figure 1.1) is well described. It is approved in the United 
States for use as a treatment for duodenal ulcers and gastroesophageal reflux disease
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(Physicians’ Desk Reference, 1998). Cimetidine’s interaction with the Hrreceptor is 
dependent, as with all Hrreceptor antagonists, on the spatial relationship between the 
heterocyclic and urea-like moiety and the receptor’s active site (Hoffman, et al., 1983). It 
behaves as a base with a pKa of 7.11 ± 0.04 (Bavin, et al., 1984). This compound is rapidly 
absorbed and excreted essentially unchanged in the urine o f rats and dogs with a terminal t* of 
*1 h, being slightly longer in humans (Brimblecombe, et al., 198S). Plasma protein binding of 
CIM ranges from 7 to 27% in rats, dogs, and humans (Taylor, et al., 1978). The major 
metabolite is a sulphoxide in all species tested (Brimblecombe, et al., 1983; Taylor, et al., 
1978) and is formed via flavin-containing monooxygenase and not CYP in swine and human 
microsomes (Cashman, et al., 1993). The mechanism by which it is removed from the vascular 
system is an active process and involves renal tubular secretion. But the clearance o f CIM 
from the body cannot be totally accounted for by renal tubular secretion route and p- 
glycoprotein transport in the renal brush border has been reported to explain the difference 
(Cacini, et al., 1982; Collett, et al., 1999; Pan, et al., 1994; Piyapolrungroj, et al., 1999). 
Cimetidine can cross the choroid plexus against a concentration gradient via an active transport 
system that is part o f the baso lateral membrane. This transport involves an FT gradient to drive 
the system and is associated with a p-glycoprotein (Collett, et al., 1999; Pan, et al., 1994; 
Piyapolrungroj, et al., 1999; Whittico, et al., 1990). Cimetidine has an acute LD» >100 mg/kg 
in rodents and dogs irrespective of the route o f administration with no treatment related 
abnormalities following chronic treatment (Brimblecombe, et al., 1985). One of the adverse 
reactions reported for CIM in humans is impotence (Mignon, et al., 1980), which may be a 
result of antagonism o f the Hrreceptor mediated effect on NO production or as an inhibitor of 
nNOS. A reduction o f at least 23% of liver blood flow has also been shown following single 
and multiple therapeutic doses o f CIM in humans (Feety, et al., 1981). In the horse, CIM has a
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volume of distribution (Vd) o f «1.2 L/kg and a terminal t* of 1.5 h (Sams, et al., 1997; Smyth, 
et al., 1990), which is similar to that reported for RAN in horses (Holland, et al., 1997). The 
Hrreceptor antagonist, zakidine (ZAL) has a longer t* (*70 h) than either CIM or RAN and a 
Vd at least 20x larger (Hunter, et al., 1996).
rV*
N  x  ^ c h 3
V  V  N N
H H cimetidine (CIM)
*ON ranitidine (RAN)
c h 3
zaltidine (ZAL)
Figure 1.1. The structure of several Hrreceptor antagonists.
Cimetidine is a proven inhibitor of CYP while ZAL is suspected of this activity (Farup, 
et al., 1988; loannoni, et al., 1986; Rendic, et al., 1984). Farup, et al. (1988) mention that this 
effect is also observed after intravenous administration of RAN, which contains a furan ring. 
The inhibition of CYP is mediated through this heme containing protein binding to structurally 
similar Hrantagonists as a 6 th axial ligand with Fe, with CIM having the lowest KD (Rendic, et 
al., 1983). The inhibition of CYP by CIM appears to be more pronounced in the presence of 
acute liver disease that in normal liver (Spceg, et al., 1982). This may be the result of a change 
in CYP isoforms present in the diseased liver due to induction by various cytokines (Sewer, et 
al., 1996). Cimetidine is known to inhibit CYP 1A2, 2C6, 2C11, 2D6, and 3A in vitro and in 
vivo (Levine, et al., 1998; Martinez, et al., 1999). Cimetidine does not interact with all heme-
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containing proteins, such as mouse catalase, where it has been shown not to be a 6 th axial ligand 
on heme-iron (Baird, et al., 1987).
When a compound produces a Type I difference spectra, this indicates that binding is 
taking place at a hydrophobic site in the protein near the heme iron, thus altering the heme 
microenvironment of CYP and/or NOS. A Type I difference spectra is the result of shift in the 
Fe** spin state from low-spin to high-spin. This shift results in a reduction of the Soret 
absorption at *420 nm and a corresponding increase at *390 nm (Lewis, 1990). Classical 
Type 1 substrates are hexobarbital, ethylmorphine, and the prostaglandins (Alvares & Pratt, 
1990; Lewis, 1996). If a Type II difference spectra is observed, then these ligands are 
interacting directly with the heme iron at the 6 th axial position (Alvares & Pratt, 1990). This 
spectral change is characterized by a decrease in absorption at *400 nm and an increase at 
approximately 430 nm. These absorption changes are a result o f Fe*** low-spin to high-spin 
shifts (Lewis, 1996). Typical Type II spectra generators are aniline, imidazole, and NO 
(Alvares & Pratt, 1990; Lewis, 1996). The interaction of CIM with CYP results in a Type II 
optical difference spectrum (Lin & Lu, 1998; Schenkman, et al., 1967) associated with the 
direct binding o f CIM to the heme moiety o f CYP. Ligand formation is both non-competitive 
(Chang, et al., 1992; Pelkonen & Puurunen, 1980) and competitive, depending on substrate 
concentration (Chang, et al., 1992; Winzor, et al., 1986). Both the cyano and imidazole groups 
of CIM have been shown to bind to the heme-iron at the 6 th axial position (Rendic, et al., 1983). 
Even the major metabolite of CIM, CIM 5-oxide, produced a Type II spectra, but had a low 
binding affinity (Rendic, et al., 1983). The binding of L-Arg to NOS results in a Type I spectra 
and is similar to the spectra obtained from CYP after binding of various substrates and suggests 
that L-Arg is altering the heme microenvironment o f NOS (Kerwin, et al., 1995).
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13. Nitric Oxide Syathaae (NOS)
The nomenclature used for the sections on NOS and all subsequent chapters will reflect 
that recommended by the International Union o f Pharmacology (Moncada, et al., 1997). Large 
volumes of work have been performed in the past several years investigating the NOS isoforms 
(NOSs, EC 1.14.13.39) and their main product, NO. This has resulted in a rapid and 
exponential increase in the knowledge base surrounding NOS and NO. The two major classes 
of NOS are eNOS and iNOS. The eNOS form has been isolated from endothelial cells, brain, 
and neuronal tissue and sub-classified as either eNOS or nNOS. Human and rat neutrophils 
have also been shown to contain mRNA for nNOS (Greenberg, et al., 1998). The constitutive 
form is responsible for the regulation of essential vasodilator tone, inhibition of platelet 
aggregation and adhesion, and it acts as a neurotransmitter in the central and peripheral nervous 
systems. This class of NOS is also Caf* dependent. Inducible NOS is predominately 
associated with macrophages, but has also been isolated from smooth muscle, hepatocytes, 
chondrocytes, microglial cells, and neutrophils (Di Rosa, et al., 1996; Evans, et al., 1996; 
Fukuto & Chaudhuri, 199S; McCall, et al., 1989). Neuronal NOS and iNOS are found mainly 
in the soluble fraction of cell or tissue homogenates (Griffith & Stuehr, 1995). It is the NO 
produced by iNOS that is responsible for the increased cytotoxicity of leukocytes against tumor 
cells and bacteria.
It has been shown that the gene encoding for iNOS is found in humans on chromosome 
17 (Chartrain, et al., 1994; Marsden, et al., 1994). This differs from eNOS and nNOS, which 
are found on chromosomes 7 (the same as CYP 3A) and 12, respectively (Marsden, et al., 
1993; Maurel, 1996). The promoter region for iNOS has been sequenced for rats, mice, dogs, 
and humans. There is *80% homology across these species (Nathan & Xie, 1994; Wang, et 
al., 1998) and all contain the typical TATA box. The transcriptional factor binding sites for
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NF-IL-6 , IFN-y response element, NF-kB, and TNF response element are highly conserved in 
all three species (Linn, et al., 1997; Lowenstein, et al., 1993; Niwa, et al., 1997; Xie, et al., 
1993).
The formation of NO in mammalian systems is through the oxidation of the terminal 
guanidinium nitrogen of L-Arg, which is catalyzed by NOS (Figure 1.2: Marietta, et al., 1988). 
Equimolar amounts o f NO and L-chruUine are formed via the intermediate V-hydroxy-L-Arg 
(L-OHArg: Marietta, 1993; Pufahl, et al., 1992; Stuehr, et al., 1991b). All isoforms of NOS 
are homodimers with a molecular weight of *300 kDa (Yui, et al., 1991), which contains a 
heme-iron protein with binding sites for the following co-substrates/cofactors: O2, nicotinamide 
adenine dinucleotide phosphate (NADPH), flavin adenine dinucleotide (FAD), flavin 
mononucleotide (FMN; Stuehr & Ikeda-Saito, 1992), L-Arg, and tetrahydrobiopterin (THB: Di 
Rosa, et al., 1996; Fukuto & Chaudhuri, 1993; Gross & Levi, 1992).
The heme found in NOS, located in the NH2-terminaI domain, is necessary for the 
conversion o f L-OHArg to NO and L-citruIline since L-OHArg appears to bind in the proximity 
o f the heme and alters the spin state o f Fe upon binding. This results in a Type I spectra and is 
similar to the spectra obtained from CYP after binding of substrates and suggests that L-Arg is 
altering the heme microenvironment o f NOS (Kerwin, et al., 1993). It is unclear if the binding 
sites for L-Arg and L-OHArg are the same (Pufahl & Marietta, 1993), but the theory has been 
suggested (Kerwin, et al., 1995). It has also been hypothesized that in the presence of O2', L- 
OHArg can be converted to NO in protein free media (Modolell, et al., 1997), but this reaction 
has been shown not to produce L-citrulline (Everett, et al., 1996). The Cys 184 residue in 
human eNOS, Cys 415 in rat nNOS, and either Glu 371 or Cys 194 for murine iNOS appear to 
be the proximal heme ligand for L-Arg binding in the various isozymes (Chen, et al., 1994;
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Crane, et al., 1998; McMillian & Masters, 199S). The guanidine* N and the guanidine C of L- 
Arg must be in close proximity to the heme-binding ligand (Griffith & Stuehr, 199S).
o o o
■n a „- "■“V'k-
NADPH ~ ~
° 2
NH
HO,
NH.
THB
NH
NH.
L-citrulline
NH
Xh 2n  n h 2
L-arginine »-a>-hydroxyarginine
Figure U .  Reaction of L-Arg catalyzed by NOS to L-citrulline and NO.
Tetrahydrobiopterin is required for formation o f the dimeric structure of all the NOS 
isozymes and for L-Arg binding (Crane, et al., 1998; Rodriguez-Crespo, et al., 1996). The 
Ca** binding protein calmodulin (CAM) is also bound to certain NOS isozymes (Cho, et al., 
1992; Marietta, 1993; Presta, et al., 1997) and in iNOS its binding region includes residues 
499 to 530 (Crane, et al., 1998). Calmodulin is needed for electron transfer, but is not required 
by nNOS for L-Arg binding (Abu-Soud & Stuehr, 1993). The binding of calmodulin in nNOS 
regulates the conversion of L-Arg to NO. This differs with iNOS, since CAM is constantly 
bound, the binding of L-Arg is the regulatory step to NO production (Abu-Soud & Stuehr, 
1993. However, iNOS does require the co-expression o f the gene encoding CAM (Ortiz de 
Montellano, et al., 1998). The flow of electrons in NOS catalyzed L-Arg metabolism is shown 
below (Stuehr, 1997). In contrast to this, while C a^ is not needed for iNOS to function,
NADPH —g-  >[FAD, FMN, and/or CAM ]— e—> heme -  F e~ + 
increased intracellular concentrations o f Ca~ will result in a reduction in iNOS mRNA 
stability, leading to a decrease in NO production (Geng & Lotz, 1995). This is opposite to
28
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
what has been proposed for eNOS and nNOS, where increases in Ca~ concentrations result in 
the synthesis o f cytotoxic amounts of NO (Takada, et al., 1998).
The extracellular concentration of L-Arg is the rate limiting factor regulating iNOS 
activity (Cheng, et al., 1996). The normal endogenous concentration of L-Arg is between 100 
and 800 mM with the KD o f eNOS <5 mM and the V -  *1.3 mmol/min/mg (Bredt & Snyder, 
1990; Chin-Dusting, et al., 1996; Stuehr, et al., 1991a) and iNOS having a Km of *17 pM 
(Hevel, et al., 1991; Frey, et al., 1994). 
l-3.a- IndndbleNOS
Inducible NOS formation is regulated primarily by induction of NOS protein synthesis 
at the transcription level via several cytokines, such as TNF-a, INF-y, and IL-ip, but not by 
LPS which must first stimulate cytokine production leading to iNOS up-regulation (Adler, et 
al., 1995; de Vera, et al., 1996; Geller, et al., 1993; Spink, et al., 1995). In horses, IL -ip 
alone does not significantly increase the activity of iNOS in vivo (Simmons, et al., 1999a). 
This regulatory mechanism for iNOS is not as rigid as that for eNOS due to the different 
physiological functions of the two classes. Once iNOS is up-regulated, NO production can be 
continued for several days, depending on the species and type of stimulus (Nathan, 1992). The 
regulation of NF-kB and its associated inhibitor, ItcBa, are the main regulators o f the 
transcription of iNOS (Peng, et al., 1995; Salzman, et al., 1996; Xie, et al., 1994) and the NF- 
kB  binding region is only found in the promoter of iNOS. Thus, NF-icB is stimulated by LPS 
resulting in the transcription o f iNOS mRNA and protein (Dfaz-Guerra, et al., 1996; Salzman, 
et al., 1996; Weisz, et al., 1994; Xie, et al., 1994). This step is blocked by NF-tcB inhibitors 
such as pyrrolidine dithiocarbamate (Sherman, et al., 1993), certain NSAIDs (Aeberhard, et 
al., 1995) and hymeniaklisine (Badger, et al., 1999). This is also the mechanism by which 
hyaluronan fragments stimulate iNOS expression in macrophages (McKee, et al., 1997; Noble,
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et al., 1996). A NF-kB binding she has also been identified in the CYP 2C11 promoter region 
(Morgan, 1997). A negative feedback mechanism exists in the regulation o f iNOS. Nitric 
oxide binds to IicBa and increases its stability, thereby further decreasing activation of NF-tcB 
(Casado, et al., 1997). However, this appears to be time dependent, as Hierholzer, et al. (1998) 
have shown. Increases in iNOS mRNA and NO lead to up-regulation o f NF-icB and 
corresponding increases in IL-6  mRNA expression.
1.3.b. L-Arginine & NO metaboBam
The semi-essential amino acid L-Arg can be metabolized by several different enzyme 
classes (Albina, et al., 1990; Andronik-Lion, et al., 1992; Boucher, et al., 1992; Stryer, 199S). 
The arginase pathway yields L-omithine and urea and is part of the urea cycle (Stryer, 199S). 
The CYPs, mainly the 3A subfamily, can convert L-Arg to NO (Andronik-Lion, et al., 1992; 
Boucher, et al., 1992; Schott, et al., 1994) and CYP 3A can be inhibited by CIM (Kuo, et al., 
199S). This is not surprising since the NOSs are a subclass of CYP enzymes (Bredt, et al., 
1991; Lowenstein, et al., 1992; White & Marietta, 1992). The product L-citrulline can be 
recycled back to L-Arg via argininosuccinate synthetase, which is co-induced with iNOS in 
macrophages (Nussler, et al., 1994; Stryer, 1995), and argininosuccinase (Cendan, et al., 1996; 
Stryer, 1995). Species differences can occur with respect to L-Arg synthesis and metabolism. 
Cats are unable to produce L-Arg in sufficient quantities to maintain physiological function, 
making L-Arg essential in the diet of this species (Rubin, 1996).
Nitric oxide gas has a high diffusion constant o f -3300 pm2/s. This allows NO to 
move 0.3-0.4 mm from its site of formation entirely by free diffusion (Lancaster, 1997). The 
biological t* o f NO reported in the literature is *100 msec (Kelm & Schrader, 1990). The 
presence of iNOS was first hypothesized based on the presence of the NO oxidized metabolites 
N02' and N 03~ and the fact that mammals maintained on low N 03' diets excreted more N 03'
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than they ingested (Stuehr A  Marietta, 198S; Stuehr A  Marietta, 1987). In the absence o f O2, 
NO dissolves in HzO and is very stable. In air it will react with 0 2  to form NO2. In H2O, 
plasma, and venous blood NO is oxidized to NO2', which is stable for several hours. In whole 
blood, NO2' and, to a much greater extent NO, are rapidly converted to N Q f via a hemoglobin 
(Hb) catalyzed oxidation (Doyle A  Hoekstra, 1981; Moncada A  Higgs, 1993; Wennmalm, et 
al., 1992). As little as 0.2 mM Hb (4% of normal blood concentration) essentially eliminates 
the presence of NO in arterial blood (Henry A  Singel, 1996; Lancaster, 1997) in <2 sec with 
ONOO" and/or nitrosyl Hb serving as possible intermediates (Doyle A  Hoekstra, 1981; Henry 
& Singel, 1996). The stoichiometry of L-Arg to L-citrulline to the formation of NOx" is 1:1:1 
(Pufahl, et al., 1992; Yui, et al., 1991). Nitrate has a terminal tM of 3.8 h in the dog (Zeballos, 
et al., 1995) and 4.8 h in ponies (Schneider A  Yeary, 1975). Little is known about how N 0 3* is 
handled by the kidneys. It has been assumed based on the molecular weights of NO2' and NO3' 
that plasma N 03‘ is freely filterable, but it has been postulated that the kidney may synthesize, 
release, and/or concentrate N 03‘ (Grisham, et al., 1996). Nitrate is reabsorbed preferentially 
over Cl' in the kidney (Greene A  Hiatt, 1953; Greene A  Hiatt, 1954).
As part of an inflammatory process, both NO and 0 2 '* are generated in relatively close 
proximity to each other, and under the proper conditions by the same enzyme system (Pou, et 
al., 1992). As a result, ONOO' may be formed (Rubbo, et al., 1994). Peroxynitrite is a very 
potent free radical believed to be at least partially responsible for the pro-inflammatory effects 
of NO (Huie A  Padmaja, 1993; Szab6 , 1996). But, by the same token, this reaction also 
decreases the damage caused by O2 - (Rddenas, et al., 1998). It is still unclear, but the theory 
beginning to emerge is that the amounts of NO and O2  produced in an inflammatory response 
must be balanced since the overproduction of either leads to localized tissue damage (Huie A  
Padmaja, 1993; Szab6 , 1996).
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At this point, we know that NO can be converted to NO2*, NO3', or ONOO*. But this 
occurs very rapidly as NO has a t* of * 1 0 0  ms and NO3'  is cleared rapidly from the body 
(Schneider & Yeary, 1975). With this in mind, it has been reported that the effect of NO lasts 
long beyond what would be expected based 00 its t*. Nitric oxide has been shown to bind to the 
free thiol group of circulating proteins in vitro and in vivo (Stamler, et al., 1992a; 1992b). In 
vivo, NO forms 5-nitrosoproteins which acts a NO adduct with activity identical to pure NO, 
but with a t* of several hours. These adducts are not biologically active as a whole (Hecker, et 
al., 1995). The concentrations of ■S’-nitrosoproteins decreased within 15 minutes of the 
administration of A^-monomethyl-L-Arg (l-NMMA), indicating that once NOS was inhibited,
S-nitrosoproteins maybe degraded to release NO in order to maintain vascular tone (Stamler, et 
al., 1992a). Hecker and coworkers (1995) have proposed that the true adduct is L-OHArg 
since it has the same biological activity as NO. These 5-nitroso proteins have shown significant 
concentration increases in the serum and synovial fluid of rheumatoid arthritis patients. The 
increase in S-nitroso proteins can be correlated with increases in N 03* in these fluids, another 
marker for increased NO production, to support a role for S’-nitroso proteins in rheumatoid 
arthritis (Hilliquin, et al., 1997). The release process of these circulating 5-nitrosoproteins may 
be similar to the metabolism of known S-nitrosoproteins such as S-nitroso-#-acetyl-D,L- 
penicillamine (SNAP) and S'-nitrosoglutathione (Askew, et al., 1995).
1-3.C. Methods of Analysis
There are several methods for detection of NO and/or its metabolites. These are gas 
chromatography-mass spectrometry (GC-MS), high performance liquid chromatography 
(HPLC), Griess assay, capillary electrophoresis, chemiluminescence, and electrochemical 
detection, just to name a few (Feelisch & Stamler, 1996). O f these, three are used on a routine 
basis for the detection and quantification o f NO, N 02‘ and/or NO3*.
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Electrochemical detection is useful in that it allows for direct measurement of NO in 
biological fluids. The detection mechanism is based on the oxidation of NO on the electrode 
surface, which produces a corresponding change in the electrical conduction o f the electrode. A 
Clark probe, similar to that used in O2 detection, is used with a platinum anode and a silver 
cathode or with a probe coated with polymeric porphyrin. A constant potential is applied and 
the direct current is measured in amperes. This method is specific for NO. The molecules O2, 
N2) CO, CO2, NOj , and N 03' will not oxidize on the electrode, but N 0 2 will cause interference 
with gas phase measurements. The probes can be calibrated by chemically generating NO 
using KNO2 and KI as a catalyst Another useful, and more reliable method at lower 
concentrations is the generation of NO from SNAP in a 0.1 M solution o f CuS04. This 
analytical technique is very sensitive with a reported limit of quantitation o f *20 nM and an 
upper limit of 10 pM (Malinski & Czuchajowski, 1996; Schmidt & Mayer, 1998).
The Griess reaction can be used to quantitate NO2* concentrations and N 03' following 
reduction to NO2* via nitrate reductase. The NO2'  is detected by reacting with sulfanilamide and 
then further derivatized via a reaction with N-{ 1 -napthyl)ethyl-enediamine to yield an azo 
product with a X,™, o f 548 nm. This method for the detection of NO2* or total NO,' is used 
extensively in NO research because of its ease of use and low cost (Schmidt & Kelm, 1996; 
Titheradge, 1998). A modification to this method uses dapsone to replace sulfanilamide. This 
change results in a decrease in the limit o f quantitation to 0.2 pM versus 1 to 5 pM for 
commercially available N 02' analysis kits. Dapsone can also be used for the detection of S- 
nitrosothiols (Marzinzig, et al., 1997).
Another method for the quantitation o f NO metabolites is chemiluminescence. This is 
accomplished via the reaction of NO with O3, but the N 02‘ or N 03‘ must first be converted to 
NO. The use o f KI as a reducing agent to convert N 02'  and NO3* to NO is well documented,
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but yields quantitation o f only NOx\  not individual metabolites. By using VCI3 in an acidic 
solution, NO, can be specifically detected. The NO produced is then reacted with 0 3 and light 
is released in die 640-900 nm range for quantitation. This is a very rapid and complete reaction 
and is not affected by NO2 (Hampi, et al., 1996; Michelakis A  Archer, 1998). It should be 
noted however, that when integrating the response o f the chemiluminescence detector, peak 
height is not linear but peak area is, thus peak area o f the standards and samples should be used 
to calibrate the assay (O’Neill, et al., 1993).
1-3.<L Similar!tin between NOS and CYP
The reactions catalyzed by iNOS are similar to those o f CYP, but differs in two main 
ways: 1) NOS requires THB, whereas CYP does not (Rodriguez-Crespo, et al., 1996), and 2) 
one of the two products o f NOS, NO, is an odd-electron free-radical species. Typical products 
of CYP oxidation are even, two-electron products (Fulcuto A  Chaudhuri, 1995). It should also 
be noted that iNOS and CYP are heme-iron containing proteins (McMillan, et al., 1992). 
There is *60% amino acid identity between CYP and iNOS (Bredt, et al., 1991; Lowenstein, et 
al., 1992; White A  Marietta, 1992). More specifically, the 10 amino acid sequence responsible 
for heme binding in CYP 3A is highly conserved between this CYP isoform and iNOS. O f 
these 10  amino acids, two are exactly the same and three others are functionally identical 
(Renaud, et al., 1993). The proximal heme ligand Cys-194 for murine iNOS (McMillian A  
Masters, 1995), corresponding to Cys-456 in CYP (Shimizu, et al., 1988), is one of the two 
amino acids which is identical in both iNOS and CYP. The similarity of cofactors and binding 
locations within the amino acid sequence indicates that the NOS isozymes are CYP reductase- 
CYP fused hybrids (Griffith A  Stuehr, 1995; Stuehr A  Ikeda-Saito, 1992). As mentioned 
previously, the CYPs, and specifically the 3A subfamily, can convert L-Arg to NO (Andronik- 
Lion, et al., 1992; Boucher, et al., 1992; Renaud, et al., 1993) and the NOSs are a subclass o f
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CYP enzymes (Bredt, et al., 1991; Lowenstein, et al., 1992; Stuehr & Ikeda-Saito, 1992; 
White & Marietta, 1992). Both iNOS and CYP have been identified in human leukocytes (Di 
Rosa, et al., 1996; Fukuto & Chaudhuri, 1995; McCall, et al., 1989; Stlrkel, et al., 1999). 
Nitric oxide regulates its own formation through a negative feedback mechanism (Casado, et 
al., 1997). Nitric oxide can also inhibit CYP at concentrations >12 pM per 100 pg of CYP 
protein. There is both a reversible and an irreversible phase. The reversible phase appears to 
be via an enzyme interaction mechanism with NO directly binding to the iron-heme active site 
of the enzyme and nitrosylating a Tyr. The irreversible phase appears to be the result of 
oxidation of key amino acids in CYP (Quaroni, et al., 1996; Wink, et al., 1993). The 
irreversible phase of inhibition by NO has also been reported in other heme-containing enzymes, 
such as NADPH oxidase, where NO reduces the generated by this enzyme (Fujii, et al.,
1997).
lJ .e . Inhibition of NOS
The NOS isozymes can be regulated at many levels by several mechanisms. These 
consist of, but are not limited to: 1) the inhibition of Ca~ influx or calmodulin binding (eNOS 
only), 2) interference with the two NADPH-dependent flavoproteins of NOS, 3) inhibition of 
heme-iron protein binding, 4) inhibition o f THB biosynthesis, 5) inhibition of L-Arg transport 
into the activated cell (Durante, et al., 1995), and 6 ) inhibition o f L-Arg metabolism with 
guanidinium and guanidinium-like containing compounds such as AG (Fukuto & Chaudhuri, 
1995). Inducible NOS can be inhibited at both the transcription and enzyme levels. 
Dexamethasone, a glucocorticoid with immunosuppressive and anti-inflammatory effects, 
inhibits the de novo synthesis of iNOS (Di Rosa, et al., 1996; Fukuto & Chaudhuri, 1995; 
Radomski, et al., 1990; Radomski, et al., 1993). This mechanism is controlled by a specific 
ligand/receptor interaction which occurs at therapeutic concentrations o f dexamethasone and is
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highly correlated with its anti-inflammatory effect This is also the mechanism by which 
dexamethasone inhibits the de novo synthesis of COX-2 (Adams, 1995; Campbell A  Halushka, 
1996; Crofford, et al., 1994), IL-2, IL-3, IL-6 , and TNF-a (Beauparlant A  Hiscott, 1996; 
Trepicchio, et al., 1996). Asthmatics exhale NO and this NO release can be inhibited by 
treatment with glucocorticoids (Curran, 1996). Cyclosporine and FK506 also inhibit 
transcription o f iNOS mRNA. They do this by binding to NF-kB and inhibiting NF-kB DNA 
binding (Beauparlant A  Hiscott, 1996; Kunz, et al., 1995). This appears to be a specific effect 
on iNOS and not eNOS (Vaziri, et al., 1998).
Aminoguanidine is reported to be a selective inhibitor of iNOS (Corbett, et al., 1992; 
Fukuto A  Chaudhuri, 1995; Griffiths, et al., 1993). Aminoguanidine is also reported to be an 
inhibitor of CYP 2C11 mRNA expression and an inducer o f CYP 2E1 expression (Sewer A  
Morgan, 1998). When AG is administered to animals, the amount of compound given and the 
duration of therapy prior to induction of iNOS is correlated to the extent of iNOS inhibition. 
Doses required to inhibit iNOS in rodents are 15-45 mg/kg IV and *400 mg/kg/day PO 
(Southan & Szabo, 1996). Treatment with AG in a rat skin flap model of ischemia/reperfusion 
significantly increased survival by inhibiting NO production from iNOS (Knox, et al., 1994). 
Aminoguanidine does not appear to be effective, however, in more chronic models of 
inflammation, especially when therapy is started several weeks after the initial insult (Fletcher, 
etal., 1998).
Aminoguanidine is a structural analog o f L-Arg and is similar to other Arg analogues 
that have been demonstrated to be inhibitors o f NOS. These include V-methyl-L-Arg, L- 
OHArg, V-amino-L-Arg, V-nitro-L-Arg, and some imidazole-containing compounds. They are 
non-specific inhibitors of NOS in that they inhibit both cNOS and iNOS. These compounds 
inhibit NOS via irreversible, competitive, and/or mechanism-based processes (Fukuto A
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Chaudhuri, 1995; Kerwin, et al., 1995). These L-Arg analogues can also effect iNOS 
production by inhibiting the L-Arg transport carrier system (Closs, et al., 1997). This 
mechanism has been exploited and a specific inhibitor of L-Arg transport has been discovered 
(Bianchi, et al., 1995). The compound AT'-nhro-L-Arg methyl ester (l-NAME) has been shown 
to decrease pain and heat following carrageenan induced knee joint inflammation in rats. This 
effect was also shown to be stereospecific (Lawand, et al., 1997). These compounds may not 
be classical anti-inflammatory drugs in that some do not reduce leukocyte infiltration and may 
actually enhance it (Iuvone, et al., 1997). Mercaptoethylguanidine is also an inhibitor o f NOS, 
with selectivity for the iNOS isoform. It inhibits both the activity and expression of iNOS 
(Zingarelli, et al., 1998).
Some of the H2-receptor antagonists also contain a guanidine functional group and have 
been shown to have several anti-inflammatory properties (Al-Haboubi & Zehlin, 1979; Al- 
Haboubi & Zehlin, 1982; Al-Haboubi & Zehlin, 1983; Ezeamuzie & Umezurike, 1989; 
Hirasawa, et al., 1987; Hirasawa, et al. 1991; Kaneta, et al., 1993; Oyanagui & Sato, 1993; 
Tasaka, et al., 1993). Small molecules resembling the guanidino moiety o f L-Arg are an 
important template from which to develop inhibitors of NOS (Hasan, et al., 1993). Some 
researchers have suggested that there are potential species differences in the affinity and 
specificity of NOS inhibitors (Kerwin, et al., 1995).
Most of the inhibitors discussed are either non-specific for NOS isoforms, such as the 
L-Arg analogs, or relatively specific for iNOS (AG and derivatives). Recent reports have 
shown that NOS inhibitors with specific binding to nNOS can and have been developed. The 
small molecule HMN-1180, a isoquinolinesulfonamide derivative, is competitive inhibitor of 
nNOS and competes for the binding she o f L-Arg in this isoform (Nishio, et al., 1998). This 
has also been reported for 7-nhro-indazole, but at high doses, this compound has been
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demonstrated to inhibit iNOS as well (Handy & Moore, 1998). The compound ibuprofen, a 
classical NSAID, has been shown, in vitro, to activate iNOS and inhibit cNOS isoforms. This 
is a very interesting result considering its known anti-inflammatory properties and low incidence 
o f adverse effects (Menzel & Kolarz, 1997). Even tetracyclines, a very well characterized class 
o f antibiotics, have been demonstrated to inhibit iNOS protein synthesis (Trachtman, et al., 
1996b). Two known inhibitors o f CYP, SKF525A and metyrapone, inhibit TNF-ct and 
enhance IL- 6  production in response to LPS administration (Morgan, 1997), possibly leading to 
effects on NO production.
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CHAPTER 2 - HYPOTHESES
My hypotheses are:
Ho: No effect o f CIM or AG treatment on any inflammatory indicator.
Hi: Cimetidine and/or AG treatment will reduce leukocyte infiltration, albumin, and 
total protein concentrations in tissue chamber fluid.
H2: Cimetidine and/or AG treatment will change concentrations of inflammatory 
mediators (cytokines and PGE2).
H3: Cimetidine and/or AG treatment will result in reduction of NO production in tissue 
chamber fluid and plasma.
H*: Inducible NOS will be elicited in equine mononuclear cells by carrageenan and 
function by a mechanism similar to that described in rodent and human cells.
The primary objectives are: 1) to determine whether NO concentrations are altered by 
CIM, 2) determine if  CIM interaction with iNOS is the mechanism by which NO production is 
decreased, 3) examine cytokine concentrations, measurement o f cell numbers and types, and 
other indices of acute inflammation with comparisons made between the ability of CIM and AG 
to affect the inflammatory response. Fourth, to attempt to determine if AG and/or the Hr- 
antagonists (CIM, RAN, and/or ZAL) alter the spin state of the Fe in the ironheme protein of 
iNOS. Cimetidine has been shown to bind to the ironheme of CYP as a 6* axial ligand due to 
its imidazole and cyano moieties (Ioannoni, et al., 1986; Rendid, et al., 1983; Rendic, et al., 
1984). Ranitdine is a weak inhibitor of CYP and has some interaction with the ironheme of 
CYP while ZAL is suspected of this type of inhibition with CYP (Farup, et al., 1988).
The approach to addressing these objectives is briefly outlined as follows. Three tissue 
chambers will be inserted subcutaneously on both sides o f the neck of six horses. After a 40
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day period for stabilization, the test tissue chamber in each animal will be inflamed with 
carrageenan. Samples of TCF and plasma will be collected for analysis of NO (as N 031, AG, 
and CIM concentrations. Complete cell counts (with differential) and total protein and albumin 
concentrations will be measured. TCF and plasma samples will be collected and frozen pending 
further analysis of PGE2, TNF-a, IL-1, and IL-6  concentrations.
Additional experiments will be undertaken in the following sequence. The first are to 
determine if AG, HIS, L-Arg, and the Hrantagonists (CIM, RAN, and ZAL) alter the spin state 
o f the Fe in the ironheme protein o f CYP and iNOS. The method o f McMillan, et al. (1992) 
will be used to determine whether Type I or Type II binding spectra are associated with the 
binding of CIM, RAN, ZAL, and AG to iNOS in equine leukocytes collected from tissue 
chambers. The second set of experiments are intended to determine the interaction of CIM with 
equine Hb, another ironheme containing protein, which is involved in the transport and 
metabolism of NO.
The potential pitfall is that CIM may not affect the production of NO in this model. 
This could be the case if carrageenan does not cause the production of cytokines that regulate 
iNOS in equine monocytes, but this is not a likely scenario. Another scenario would be that 
carrageenan does not cause the induction of iNOS but induces various isoforms of CYP, 
resulting in increased NO via a non-NOS pathway. It is also possible that CIM simply does not 
regulate iNOS, either through interference with an H2 receptor on monocytes or through a direct 
interaction with iNOS. Another potential pitfall is that none of the proposed mechanisms that 
are being studied could be the one that is used by CIM to decrease NO production. This 
appears to be unlikely, but it is a possibility.
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CHAPTER 3 - CIMETIDINE INHIBITS NITRIC OXIDE ASSOCIATED NITRATE 
PRODUCTION IN A SOFT-TISSUE INFLAMMATION MODEL IN THE HORSE
3.1. Introduction
Nitric oxide is a volatile, lipid soluble, and reactive molecule which is known to be 
involved in many physiologic functions. The formation of NO in mammalian systems is 
mediated by NOS, which catalyzes the oxidation o f the terminal guanidinium nitrogen o f L-Arg 
(Hibbs, et al., 1988; Iyengar, et al., 1987; Marietta, et al., 1988). The high output iNOS 
contains a heme-iron protein with binding sites for five cosubstrates/cofactors: O2, NADPH, 
FAD, FMN, and THB (Di Rosa, et al., 1996; Fukuto & Chaudhuri, 1993). This isoform is 
predominately associated with macrophages, but has also been isolated from smooth muscle, 
hepatocytes, microglial cells, and neutrophils (Di Rosa, et al., 1996; Fukuto & Chaudhuri, 
1995; McCall, et al., 1989). It is the NO produced by iNOS that is primarily involved in the 
inflammatory response to noxious stimuli and the increased cytotoxicity of macrophages against 
tumor cells and bacteria.
Histamine type 2 receptors are located in neutrophils, lymphocytes, and blood vessels 
lining the synovial space (Grennan, et al., 1975; Hill, et al., 1997; Mannaioni, et al., 1988). 
The suppression o f human cytolytic T cell function in lymphocytes is mediated by HIS through 
H2 receptors (Khan, et al., 1989). Histamine plays an important role in the regulation of 
various cytokines associated with inflammation. It decreases the expression of IL-6 receptors 
on various cell types with a mechanism hypothesized to be linked to precep tors (Merdtey, et 
al., 1991). It can alter IL-6 synthesis and this synthesis is inhibited by CIM and RAN via an 
H2-receptor mechanism (Vannier & Dinarello, 1994). Histamine increases IL-lp mRNA levels 
via H2-receptors and treatment with an Hrreceptor antagonist decreases IL -ip concentrations 
(Vannier & Dinarello, 1993). Nitric oxide, also an important mediator in inflammation, has its
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synthesis upregulated by HIS through both H( (Kelm, et al., 1993) and H2 mechanisms while 
H^receptor agonists reduce this synthesis (Mannaioni, et al., 1997). Several H r receptor 
antagonists have been demonstrated to dramatically reduce HIS and carrageenan-induced edema 
in the rat with CIM being the most potent of those tested (Al-Haboubi A  Zeitlin, 1979; Al- 
Haboubi & Zeitlin, 1982; Al-Haboubi A  Zeitlin, 1983; Ezeamuzie & Umezurike, 1989; 
Kaneta, et al., 1993).
The Hrreceptor antagonists are reported to improve the function of the immune system 
in immunosuppressed subjects (Anderson, et al., 1983; Canning, et al., 1993; Email, et al., 
1984; White A  Ballow, 1983). Upon treatment with Hrreceptor antagonists, IL-2 production 
in lymphocytes is increased (Gifford A  Tilberg, 1987). Rezai and coworkers (1990) have 
suggested that this change in immune function is due to Hrantagonist reversal of the inhibition 
of IL-2 gate expression caused by HIS. Interleukin-2 increases the expression of Hrreceptors 
on lymphocytes and the addition o f CIM decreases the cytotoxic effect of IL-2 (Shibata, et al.,
1992). Hirasawa’s group (1991) reported that when Hrreceptor antagonists were administered 
after induction of inflammation, neutrophil numbers increased at the site of inflammation, but 
did not increase following Hi-receptor antagonist treatment In HIS induced edema, Hi- 
antagonists decreased edema formation and Hrantagonists did not However, when NO was 
added (generated from NaNOz, nitroprusside, or hydroxylamine) to the model, CIM decreased 
the extent of edema formation (Oyanagui & Sato, 1993). Similar results were reported by 
Hirasawa’s group (1987) in which CIM blocked the inhibitory action of indomethacin on 
leukocyte accumulation but had no effect on edema formation. Cimetidine, but not RAN, has 
also been shown to reduce basal cGMP (the secondary messenger involved in NO signaling) 
levels in culture (Schrdder A  Schrfir, 1990).
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Inducible NOS activity can be inhibited directly by compounds with guanidinium and 
guanidinium-likc moieties, such as AG (Gross, et al., 1990; Hibbs, et al., 1987; Moore, et al.,
1990). Aminoguanidine (Figure 1.1) is reported to be a relatively selective inhibitor of iNOS 
(Griffiths, et al., 1995; Griffiths, et al., 1993; Laszlo, et al., 1995; Misko, et al., 1993). It acts 
as a competitive inhibitor of iNOS, not as a substrate leading to NO formation (Griffiths, et al., 
1995; Griffiths, et al., 1993; Laszlo, et al., 1995; Misko, et al., 1993).
Some of the Hrreceptor antagonists also contain a guanidine functional group (Figure 
1.1). Cimetidine and other antagonists have been used for many years to control gastric acid 
secretion in man and in domestic species. It has been shown that at least two o f the compounds 
in this class, CIM and RAN, bind to the heme-iron portion of CYP (Rendi<5, et al., 1984) to 
inhibit CYP activity, producing a decrease in the biotransformation o f various xenobiotics 
which are metabolized by the CYP monooxygenases Ooannoni, et al., 1986; Rendtf, et al., 
1984). It has recently been demonstrated that iNOS is also an isoform o f CYP (Renaud, et al.,
1993), and it contains a CYP reductase which allows it to be catalytically self-sufficient (White 
& Marietta, 1992).
The fact that guanidine containing compounds such as CIM inhibit CYP activity, and 
the finding that NOS is also an isoform o f CYP (Renaud, et al., 1993), suggests that CIM 
could block the production of NO catalyzed by iNOS. The hypothesis that iNOS activity could 
be so inhibited was tested with CIM as the putative blocker and AG as a positive control for 
inhibition, using the carrageenan inflammation model in the horse previously described by 
Guthrie and coworkers (1996). The effect o f CIM on cytokine and PGE2 production was also 
of interest due to Hrreceptor regulation o f these inflammatory mediators. This study was 
divided into two trials. Trial 1 was designed to test the effect of CIM (three IV doses at 3 
mg/kg) on NO derived N 03', using AG as a positive control. The second trial was designed to
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reduce the occurrence o f NO3' from dietary sources in plasma and TCF, and to confirm the 
effect of CIM using a higher dose (seven IV doses at 6  mg/kg).
3 J . Materials A Methods 
32 j l  Trial I
Animals: Six female Thoroughbred horses belonging to the Equine Veterinary
Research Program herd, and ranging in age from 8-16 years and 468-523 kg were used in this 
study. All animals were part of a routine health maintenance program and clinically healthy. 
They were maintained on Bahia grass pasture supplemented with Bermuda grass hay between 
treatments and fed only pelleted feed during the treatments. Water was available ad libitum. 
The animals were taken off pasture and placed in a mat-floored stall bam *16 h prior to the day 
-1 samplings. The research protocol was approved by the LSU Institutional Animal Care and 
Use Committee prior to initiation of the study.
Tissue Chambers: Delrin® AF thermoplastic (Polymer Corporation, Reading, PA) cup 
type tissue chambers faced with a reinforced silastic membrane (SIL-TEC class VI USP 
sheeting, Technical Products Inc. of GA, USA, Decatur, GA) were implanted subcutaneous!y 
under general anesthesia as described by Guthrie, et al., (1996). Anesthetized horses were 
placed in lateral recumbency and each horse received three chambers, two on one side o f the 
neck and one on the other. Chambers on the same side o f the neck were placed at least 150 mm 
apart, horizontally. The chambers were stabilized by suturing to the underlying tissue bed. The 
tissue chambers were oriented with the collecting cup holes being most dorsal on the neck so 
that fluid would accumulate in the ventral aspect of the cup. Animals were treated orally for 24 
h prior to surgery and 10 days post-surgery with 2 g phenylbutazone (Butatabs E, Burns 
Veterinary Supply, Carrollton, TX), 2 g trimethoprim, and 10 g sulfadiazine (Tribrisscn®,
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Mallinckrodt Veterinary, Mundelein, IL). The subjects were allowed to recover from the 
surgical intervention for at least 45 days before commencement of the study.
Experimental design- The study was comprised of three time-sequenced treatments, as 
summarized in Figure 3.1. The purpose o f Treatment 1 was to establish each animal’s response 
to carrageenan. Physiologic saline (NaCl) was administered as a control for similar intravenous 
injections of either CIM or AG. Each o f the six mares received three IV (jugular) injections of 
10 mL of NaCl (0.9% sterile saline, USP, Baxter Healthcare Corporation, Deerfield, IL) at 12 
h intervals. Coincident with the 3rt dose, one mL of 1% sterile carrageenan (X-carrageenan; 
Sigma Chemical Co., S t Louis, MO) was instilled into chamber A. Blood and TCF from 
chamber A (inflamed; NaCl-I) and chamber B (non-inflamed control; NaCl-N) were sampled at 
-24, 0 (immediately prior to carrageenan instillation), 4, 8 , and 12 h and at 1, 2, 3, 5, and 7 
days post-instillation. Blood samples for cell counts were collected into 7 mL evacuated tubes 
containing EDTA (Vacutainer®, Becton Dickinson, Rutherford, NJ). Blood for NO (as NOj*), 
TNF-oc, IL-1, IL-6 , PGE2, CIM, and AG analysis was collected into 15 mL heparin containing 
evacuated tubes. Samples (0.5 to 12 mL) o f TCF were collected under aseptic conditions and 
transferred immediately to 7 mL EDTA (1 to 2 mL of sample) and 15 mL heparin containing 
evacuated tubes (remaining sample).
The purpose of Treatments 2 and 3 was to compare the effects o f CIM and AG on the 
parameters measured in Treatment 1. Treatments 2 and 3 were designed as a 2 x 3 crossover in 
which three mares received CIM (3 mg/kg; Tagamet®, SmithKline Beecham Pharmaceuticals, 
Philadelphia, PA) and three received AG (25 mg/kg) according to the protocol used in 
Treatment 1, but following a four week washout period (Treatment 2). The procedure was 
repeated (Treatment 3) following a further four week washout period except that the horses 
which received CIM in Treatment 2 received AG, and vice versa. In Treatment 2, chamber B
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Figire 3.1. Diagram of relationship between dosing (A ) of NaCl, CIM, or AG, instillation of carrageenan into the test chamber (a), and 
sampling of TCF and plasma (x) for Trial 1.
was the test (inflamed) chamber; in Treatment 3 it was chamber C. An uninflamed chamber 
(B) was designated as a control chamber and was sampled in Treatment 1; there were no 
control chambers designated for Treatments 2 or 3. Each chamber was inflamed once and 
chamber B was the only chamber used twice.
The dosage used for CIM was based on the dose recommended for treatment of 
gastrointestinal ulcers in horses (Stiles, et al., 1990) and the disposition of CIM in horses 
(Smyth, et al., 1990). The dosage regimen for AG was based on the absorption and 
distribution parameters described for man and mice (Bowman, et al., 1996; Foote, et al., 1995) 
and NO inhibition results reported by Corbett, et al. (1992) and Griffiths, et al. (1993). The 
effective molar concentrations reported for AG in the above studies were converted to jig/mL 
values, which were then used as target concentrations for calculating a dosage regimen. The 
relatively high concentrations needed to produce efficacy in mice were also considered when the 
final dose was calculated (Corbett, et al., 1992; Griffiths, et al., 1993).
3.2. b. Trial 2
Animals: Six female Thoroughbred horses (five from Trial 1) belonging to the Equine 
Veterinary Research Program herd, and ranging in age from 8-16 years and 455-500 kg were 
used in this study. They were fed only pelleted feed during the treatments and for 14 days prior 
to the initiation of treatments. Water was available ad libitum.
Experimental Design: Each horse had blood and TCF samples collected and analyzed 
for N 03~ prior to initiating treatment Studies commenced when detectable N 03‘ fell below 10 
|iM in both plasma and TCF. A randomized complete crossover design was used in which three 
of the mares received NaCl first and the other three received CIM first Each of the six mares 
received seven IV injections o f either 10 mL of NaCl or CIM ( 6  mg/kg) at 8  h intervals. 
Coincident with the 7* dose, one mL o f 1% sterile carrageenan (X-carrageenan; Sigma
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Chemical Co., S t Louis, MO) was instilled into chamber A. The crossover was conducted 
after a one-week washout period. Blood and TCF from chamber A (inflamed; NaCI-I) and 
chamber B (non-inflamed control; NaCl-N) were sampled at -48, 0 (immediately prior to 
carrageenan instillation), 4, 8 , 12, and 24 h post-instillation. Blood for NO (as N 03") and CIM 
analysis was collected as in Trial I. Samples (0.5 to 7 mL) of TCF were also collected as 
previously described. Each chamber was inflamed once and chamber B was the only chamber 
used twice.
3.2.C. Assays
Blood samples collected for N 03\  IL-1, IL-6 , TNF-o, PGE2, CIM, and AG analysis 
were centrifuged at * 1 0 0 0  xg  to obtain plasma, which was aspirated and stored in 
polypropylene cryovials at -70°C until assayed. Vials for PGE2 samples contained 10 pg of 
BW540C (provided by Dr. Peter Lees, Royal Veterinary College, London, UK) to halt its 
continued formation (Higgins, et al., 1987a). Samples of TCF for N 0 3‘ analysis were 
transferred without centrifugation where as samples for all other analytes were processed after 
centrifugation and stored in the same manner as the corresponding plasma sample.
NOi~ analysis: Quantitative analysis of N 03' was conducted with a chemiluminescent 
detector (Sievers Nitric Oxide Analyzer NOA™, Model 280, Sievers Instruments, Inc., Boulder, 
CO). The method is based on a gas-phase chemiluminescent reaction between NO and ozone. 
In the absence of 0 2, NO dissolves in H2O and is very stable. In air, it will react with 0 2 to 
form N 02. In H2O and plasma, NO is oxidized to N 02", which is stable for several hours. In 
whole blood, N 02‘ and, to a much greater extent NO, are rapidly converted to N 03‘ via a Hb 
catalyzed oxidation (Doyle & Hoelcstra, 1981; Moncada & Higgs, 1993; Wennmalm, et al., 
1992). As little as 0.2 mM Hb (4% o f normal blood concentration) essentially eliminates the 
presence of NO in arterial blood (Henry & Singel, 19%; Lancaster, 1997) in <2 sec with
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ONOO' and/or nhrosyl Hb serving as a possible intermediates (Doyle & Hoekstra, 1981; Henry 
& S ingel, 1996).
The N 03' in plasma and TCF was converted to NO by reduction with a saturated 
solution o f VCI3 in In  HC1. Samples of either plasma or TCF were removed from -70°C 
storage and brought to room temperature (»25°C). Samples (100 jiL) were placed in a 1.5 mL 
polypropylene microcentrifuge tube that had been rinsed 3x with HPLC grade H2O. 
Trichloroacetic acid (TCA; 10%; 100 |iL) was then added to each sample and the tube was 
capped and vortexed. Samples were incubated for 15 min at ambient temperature and then 
centrifuged at *2000 xg  for S min. A three jiL aliquot was then injected into the reaction 
chamber containing the VC13 solution to convert the NOs* in the sample to NO. The NO formed 
from this reduction then reacted with ozone in the detector to release chemiluminescent energy 
which was recorded by the detector as voltage using an analog scale.
A standard curve (10 to 200 jiM) and quality control (QC) samples (25, 60, and 125 
pM) were made in HPLC grade H2O on each day that samples were analyzed. Standards, QC 
samples, and unknowns were analyzed in triplicate. Concentrations were quantitated using 
peak area of voltage output from the detector and slope/intercept from linear regression analysis 
of the standard curve. The limit of quantitation was 10 11M and was defined as the 
concentration which gave a signal to noise ratio >5. Intra-day accuracy and precision were £ l 1 
and 7.9%, respectively, while inter-day accuracy was £ l 1% and precision £14%. Carrageenan, 
heparin, HPLC grade H2O, and TCA samples were analyzed and found to have N0 3~ 
concentrations of <10 jim . Cimetidine and AG were also assayed across a range o f 
concentrations that bracketed those measured in samples collected. For CIM, concentrations of
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<50 pg/mL bad <10 pM N 03‘ while AG showed the same level o f N 03‘ for concentrations <200 
pg/mL, which is similar to results reported by Greenberg, et al. (1995).
IL-1: Quantitative analysis o f IL-1 was conducted using a bioassay with cell line DIOS 
similar to that previously described by Sc hook, et al. (1992). Briefly, a standard curve was 
made by diluting the IL-1 standard in assay medium without T-cell growth factor or other 
cytokines. Test samples were also prepared with any dilutions being made with assay medium. 
Final volume in each well of a 96-well plate was 100 pL. The D10S cells were washed three 
times in culture medium (Dulbecco’s-PBS w/ 1% HI-CPSR-2). Prior to the last wash, the cells 
were incubated at room temperature for 15-30 min to allow for incorporation of any remaining 
surface-bound growth factor. After the final wash, 100 pL of the cell suspension (1 x 10s 
cells/mL) was added to each well. The 96-well plates were then incubated at 37°C in an 
atmosphere of 5% CO2 for 48 h. At the end of the incubation, proliferation of the cells was 
measured by a fluorimetric method 20 h after the addition o f Alamar Blue dye into each well. 
The standard curve ranged from 0 to 100 units of activity/mL.
IL-6 : Quantitative analysis of IL- 6  was conducted using a bioassay with cell line 
7TD1 as previously described (Myers, et al., 1995; Myers, et al., 1997). Briefly, a standard 
curve was made by diluting the IL- 6  standard in assay medium without T-cell growth factor or 
other cytokines. Test samples were also prepared with any dilutions being made with assay 
medium. Final volume in each well of a 96-well plate was 100 pL. The 7TD1 cells were 
washed three times in culture medium (Dulbecco’s-PBS w/ 1% HI-CPSR-2). Prior to the last 
wash, the cells were incubated at room temperature for 15-30 min to allow for incorporation of 
any remaining surface-bound growth factor. After the final wash, a 100 pL aliquot of the cell 
suspension (1 x 10s cells/mL) was added to each well. The 96-well plates were then incubated 
at 37°C in an atmosphere of 5% CO2 for 48 h. At the end of the incubation, proliferation of the
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cells was measured by a fluorimetric method 20 h after the addition of *lam«r blue dye into 
each well. The standard curve ranged from 0 to 100 units of activity/mL.
TNF-q: Quantitative analysis of TNF-a was conducted using a bioassay with cell line 
W EHI164 clone as previously described (Myers, et al., 1995; Myers, et al., 1997). Briefly, a 
standard curve was made by diluting the TNF-a standard in assay medium without T-cell 
growth factor or other cytokines. Test samples were also prepared with any dilutions being 
made with assay medium. Final volume in each well of a 96-well plate was 100 pL. The 
WEHI cells were washed 3x in culture medium (Dulbecco’s-PBS w/ 1% HI-CPSR-2). Prior to 
the last wash, the cells were incubated at room temperature for 15-30 min to allow for 
incorporation of any remaining surface-bound growth factor. After the final wash, 100 pL of 
the cell suspension (1 x 10s cells/mL) was added to each well. The 96-well plates were then 
incubated at 37°C in an atmosphere of 5% CO2  for 48 h. At the end of the incubation, lack of 
proliferation of the cells was measured by a fluorimetric method 2 0  h after the addition of 
alamar blue dye into each well. The standard curve ranged from 0 to 33 units o f activity/mL.
PGE? analysis: Quantitation of PGE2 was accomplished using a commercially
available (Neogen* Corporation, Lexington, KY) enzyme-linked immunosorbent assay (ELISA) 
kit. Samples (0.5 mL) were acidified with 100 pL o f In  HC1 and then extracted with 4.5 mL of 
ethyl acetate (EA). The EA layer was separated by placing the samples in an acetone/dry ice 
bath and decanting the EA layer into a clean tube. The resulting samples were evaporated 
under a N2 stream at room temperature. The residue was then stored at -7°C for *12 h prior to 
PGE2 analysis.
The ELISA kit contained a known standard for making spiked PGE2 plasma standards 
over the range of 0.1 to 10 ng/mL. Extracted samples were removed from the freezer and 
warmed to room temperature. The samples were then reconstituted in 0.5 mL of manufacturers
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extraction buffer and vortexed. A fifty pL aliquot of each sample was placed in a well of the 
96-well plate which contained the antibody. Samples were assayed in duplicate and a standard 
curve was assayed with each plate. A 50 pL aliquot of enzyme conjugate was then added to 
each well, and the plate was gently shaken to mix contents and covered for 1 h at *25°C. After 
incubation, each well of the plate was washed 3x with 300 pL of commercial wash buffer 
provided with the kit. Finally, 130 pL of enzyme substrate was added to each well and the 
plate was covered and incubated for 30 min. After the second incubation, the plate was read on 
a microplate reader using a >.=630 nm.
To calculate the standard curve, a PGE2 naTve sample was assayed as part of the 
standard curve. The average of each standard and unknown was determined with the 0 ng/mL 
standard designated Bo. The average of each standard was the divided by Bo to obtain % 
maximal binding, which was plotted against concentration and a curve fitted to the data. This 
curve was used to calculate the concentrations of the unknowns.
CIM analysis: Quantitative analysis for CIM in plasma and TCF samples in both 
experiments was conducted using HPLC with ultraviolet (UV) detection similar to that reported 
by Sams, et al. (1997). The HPLC system consisted o f two pumps (Model SOI, Waters 
Chromatography, Milford, MA), an automated sample injector (WISP, Waters 
Chromatography, Milford, MA), and a variable wave length UV detector (Model 484, Waters 
Chromatography, Milford, MA) which were attached via a System Interface Module (Waters 
Chromatography, Milford, MA) to a personal computer which controlled sample collection and 
integration (Baseline* Waters Chromatography, Milford, MA). The column was a 15 cm x 3 
mm C ig reverse phase column (Phenomenex, Torrence, CA) immediately preceded by a 2 p 
column frit. The mobile phase used was 0.033% HjP04:HPLC grade methanol (MeOH; 90:10)
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with a flow rate of 0.2 mL/min after being filtered and degassed. The detection was 
accomplished using a X=228 nm.
Plasma standards were prepared by adding an appropriate amount of CIM standard 
solution to CIM naive equine plasma to produce concentrations of 0.1 to 10 pg/mL. Plasma 
standards were prepared and analyzed on each day that unknown samples were assayed. 
Quality control (QC) samples (0.25, 1.2, and 6 pg/mL) were prepared at the start of the 
analysis, aliquoted, and frozen to be thawed in pairs on each day that unknowns were analyzed.
CIM was extracted from plasma and TCF samples using solid phase extraction (SPE) 
columns containing a C,g bonded sorbent (Bakerbond, J.T. Baker, Phillipsburg, NJ). The 
cartridges were prepared, after being placed on a vacuum manifold (Supelco, Bellefonte, PA) 
maintained at <5 mmHg, for use by washing with one mL of HPLC grade MeOH, followed by 
one mL HPLC grade H2O. The SPE column was not allowed to reach dryness. One mL of 
sample, after having 50 pL of 100 pg/mL RAN (internal standard) added, was placed onto the 
column and allowed to flow through. The column was then washed with one mL of H2O (2 x) 
and air dried for at least 3 min. The column was eluted with 250 pL of MeOH (3x) and dried 
under N2. The sample was reconstituted with 150 pL o f mobile phase and vortexed. This 
volume was transferred to autosampler vials and 20 pL was injected onto the HPLC system.
Concentrations o f CIM were determined from integrated peak height ratios of CIM and 
an internal standard for each standard and unknown sample. The peak height ratio of each 
standard was plotted against the corresponding known concentration o f CIM. Linear regression 
analysis was performed to obtain a regression equation using a weighting factor of 
[concentration]'1. All standards, QCs, and unknowns were assayed in duplicate and the mean of 
the pair of determinations was reported. Samples found to contain CIM at a concentration 
greater than the upper limit of the standard curve were reassayed using a smaller aliquot of
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sample and an appropriate amount o f CIM naive plasma. Recovery was >80% across the 
range of the standard curve and for the internal standard. Inter- and intra-day accuracy was 
<±15% with precision <±15%.
AG analysis: Quantitative analysis for AG in plasma and TCF samples was conducted 
using HPLC with UV detection similar to the derivatizatkm procedure reported by Foote, et al. 
(1995). The column was a 15 cm x 3 mm CN reverse phase column (Phenomenex, Torrence, 
CA) immediately preceded by a 2 n column frit. The mobile phase used was 
MeOH:acetonitrile:0.01M 1 -heptanesulfonic acid and NaH2P04 (10:10:80) with a flow rate of 
0.4 mL/min after being filtered and degassed. The detector was set at >.=313 nm.
Plasma standards were prepared by adding an appropriate amount of AG standard 
solution to AG naive equine plasma to produce concentrations of 0.05 to 10 pg/mL. Plasma 
standards were prepared and analyzed each day that unknowns were assayed. Quality control 
samples (0.25, 0.75, and 7.5 yig/mL) were prepared at the start of the analysis, aliquoted, and 
frozen to be thawed in pairs on each day unknowns were analyzed.
For analysis, 0.5 mL of 7.5% TCA was added to 0.5 mL o f sample, vortexed, and 
centrifuged at * 2 0 0 0  x g  for 2 min. The supernatant was decanted into a disposable glass 
culture tube to which 1 0 0  pL o f the derivatizing reagent was then added (6 -methyl-2 -pyridine- 
carboxaldehyde; Sigma Chemical Co., S t Louis, MO). The samples were then placed in an 
oven for 10 min at *95°C and subsequently transferred to autosampler vials. The injection 
volume was 200 pL.
Concentrations o f AG were determined from integrated peak heights of AG for each 
standard, QC, and unknown sample. The peak heights o f each standard were plotted against 
the corresponding known concentration of AG. Linear regression analysis was performed on 
the standards to obtain a regression equation using a weighting factor of [concentration]'1. All
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standards, QCs, and unknowns were assayed in duplicate and the mean of the pair of 
determinations was reported. Samples found to contain AG at a concentration greater than the 
upper limit of the standard curve were re-assayed using a smaller aliquot o f sample and an 
appropriate amount of AG naive plasma.
Analysis of Results: Plasma and TCF leukocyte, cytokine, albumin, total protein, and 
NCV concentrations were evaluated for significant differences by comparing area under the 
curve (AUC) values (Al-Haboubi & Zeitlin, 1982; Al-Haboubi & Zeitlin, 1983; Lesser, et al, 
1980) and time of maximal response (T— ) values (cytokines only). The AUC’s were 
calculated as AUCi* using the trapezoidal rule (Gibaldi & Perrier, 1982) with the non- 
compartmental model of WinNonlin (Scientific Consulting Inc., Apex, NC) for the periods of 
- 1—>1, - 1—>3, and -1-V7 days for leukocyte and NO3'  data (-2-»l for Trial 2). For cytokines, 
the periods o f -1—>0.5, -1—>1, -1—>2, and -l->3 days were evaluated, as appropriate. It was 
also determined a priori that the 4, 8 , and 12 h NO3' concentrations in plasma and TCF would 
be compared. Statistical analyses o f the data were performed using the nonparametric 
Friedman Test was used to evaluate the significance of AUC, T»_. and N 03' concentrations and 
is the equivalent of an Analysis of Variance Test (ANOVA) for parametric data. The Wilcoxon 
Sign Rank Test was employed for NO3* concentrations in Trial 1 and is similar to ANOVA for 
repeated measures, but does not have an exact equivalent parametric test. Nonparametric tests 
were used because the assumption of a normal distribution could not be met due to the sample 
size in the trials. Comparisons were made using ranked values, for each time period, within 
each animal for NaCI-I, NaCl-N, CIM, and AG. If a significant difference (p £ 0.05) was 
found, Tukey’s multiple-comparison test (p £  0.05; Daniel, 1990) was performed to determine 
which treatments were significantly different. Estimates of the pharmacokinetic parameters for
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plasma CIM and AG were determined for each individual animal using non-compartmental 
analysis (Gibaidi & Perrier, 1982).
33. Resalts 
3J.a. Trial I
Nitric Oxide: Mean NO3'  concentrations in plasma increased markedly during the first 
12  h following instillation of carrageenan into the test chamber, but returned to baseline values 
by 24 h (Figure 3.2). Mean values remained low but variable from day 1 through day 7. The 
same pattern was observed for TCF following test chamber inflammation (Figure 3.3). 
Comparison o f concentrations of NO3'  in plasma and TCF for the first 12 h after instillation of 
carrageenan into the test chamber showed that peak ( 1 2  h) values in that chamber approximated 
those in both plasma and the control chamber (Table 3.1). It is also apparent that neither CIM 
nor AG had an effect on N 03* concentration, in either plasma or TCF, at 4 or 8  h post­
inflammation. At 12 h, however, both agents produced absolute values which were 
significantly lower than those observed when NaCl was used as the treatment
Analysis of the NO3' concentrations at 4, 8  and 12 h after carrageenan instillation was 
conducted using the Wilcoxon Sign Rank Test to detect changes in N 03‘ concentrations in 
plasma and TCF. Instillation of carrageenan into the test chamber significantly increased the 
concentration of NO3* in plasma and the control chamber in parallel with the rise in NO3' 
concentration in the test chamber following NaCl treatment over the period of 4 to 12 h, but not 
following AG or CIM treatment when measured over the same period. In fact, the values for 
concentrations at each time point were nearly identical in the three sets of samples.
Analysis of the data using Friedman’s test with multiple comparison (Table 3.2) 
showed that median NO3' concentrations in plasma were significantly (p < 0.03) lowered by 
both CIM and AG treatments at 12 h. The same was true for NO3' concentrations in TCF.
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There was no difference between CIM or AG treatments - both were equally effective in 
lowering N 03‘ concentrations in both plasma and TCF compared to NaCl treatment.
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Figure 3.2. Mean (± SD) plasma N 03* concentrations following NaCl, CIM, or AG treatment 
from Trial I. NaCl, CIM (3 mg/kg), and AG (25 mg/kg) were administered at -1, -0.5 
and 0  days.
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Figure 3 3 . Mean (± SD) TCF N 03' concentrations following NaCl, CIM, or AG treatment 
from Trial 1. NaCl, CIM (3 mg/kg), or AG (25 mg/kg) were administered at -1, -0.5 
and 0  days.
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Tabic 3.1. Concentration of N03' at 4 ,8 , and 12 h after carrageenan instillation in plasma and TCF from Trial 1.
NaCI-N NaCI-1 CIM AG
Parameter median range median range median range median range
Plasma N03‘ 4 h (pM) 
p=0.8416
- * 21“ <10-51 29 <10-43 31 <10-44
Plasma NO)' 8  h (pM) 
p=0.6768
- - 32 <1 0 - 6 6 33 <10-50 40 <10-76
Plasma NO)' 12h(pM) 
p=0.0036
- • 56*’“ 32-91 33b <10-45 32b 19-55
TCF NO)' 4 h (pM) 
p=0.7187
18* <10-32 2 0 *^ <10-43 15 <10-40 2 0 <10-37
TCF NOj* 8  h (pM) 
p=0.7827
33 <10-44 28* <10-48 28 <10-38 31 23-87
TCF NO)' 12h(pM)
p=0.0008
50*1* 34-61 56*** 39-90 29b <10-44 38b 24-94
Those treatment medians with different lettered superscripts, within a parameter, are significantly different at the p^O.05 level. Those 
parameters with medians wftboat sapencripts had no significant differences upon multiple comparison. Those treatment medians with Hhe 
Greek letter sapencripts are significantly different at the p £ 0.0S level based on the Wilcoxon Sign Rank Test. The p values shown with the 
parameter is the value obtained from the Friedman’s test. NaCI-N = saline treatment non-inflamed; NaCI-I = saline treatment inflamed; CIM = 
cimetidine treatment; AG = aminoguanidine treatment. NaCI-N and NaCI-I correspond to Treatment I. There were no control chambers 
sampled during Treatments 2 & 3.
Data were also analyzed as AUC of NQf concentrations from -1 day to either 1, 3, or 7 
days (Table 3.2). Data in Table 3.2 represent only those values which were significant (p £ 
0.05) using Friedman's test for ranked AUC values. Multiple comparison analysis revealed 
significant differences in plasma AUC values (AUC.i_i, AUC.1-,3, and AUC.t_»7) for CIM 
compared to NaCl treatment In addition, all three AUC values for TCF data were significantly 
lowered by both CIM and AG treatment compared to NaCl. Again, there was no difference in 
the effectiveness of CIM vs. AG treatments. It is also notable that there was no difference in 
N O 3' values for the test vs. control chamber in NaCl treated animals.
Leukocyte response: Neutrophil (Figure 3.4), basophil, eosinophil, monocyte (Figure 3.S), and 
lymphocyte (Figure 3.6) concentrations were measured in venous blood and in TCF as AUC 
values, in the same manner as the N 03* data. The data in Table 3.3, which contains only values 
for which significance (p £  0.03) was indicated by Friedman’s test, clearly show that TCF 
concentrations of neutrophils increased from days -1 to 3, compared to the control chamber. 
When the data were expressed as the percent of cells*day (%«day) which were neutrophils, 
there was also a difference between inflamed and non-inflamed chamber for AUC.i-** but not 
for AUC.1-,7. Thus, while the numbers of neutrophils infiltrating the test chamber in response 
to carrageenan increased, the percent of total cells which were neutrophils increased 
significantly over the short term only, and not over the full 8  day term of the study.
Treatment with neither CIM nor AG produced a significant reduction in neutrophil 
concentrations in the test chamber compared to NaCl treatment. This was also true for the 
percentage of cells which were neutrophils. Lymphocyte concentrations in the control, NaCl 
treated test chamber and CIM treated test chamber were not different, though the numbers in 
the test chamber following AG treatment were somewhat higher than in the others. There were 
no differences in the percentage of cells which were lymphocytes in TCF related to any
59
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Reproduced 
with 
perm
ission 
of the 
copyright ow
ner. 
Further reproduction 
prohibited 
without perm
ission.
Table 3.2. Median and range of plasma and TCF N03‘ AUCs from Trial I.
NaCl-N NaCM CIM AG
Parameter median range median range median range median range
Plasma NO3' AUC.i_*i 
(|imole*day/L) p=0.0347
• - 46* 30-64 37b 20-46 39%b 24-52
Plasma NO/AUC.,-* 
(pmole*day/L) p=0.0347
- - 72* 50 -107 57b 40-66 59*h 44-72
Plasma NOj AUC.t_,7 
(pmole»day/L) p=0.0347
• • 141* 90-176 9 7b 80-106 99*b 84-112
TCFNOj’AUC.,.,, 
(pmole*day/L) p=0 .0001
47* 38-76 58* 38-101 36b 22-45 34b 29-68
TCFNO3 AUC.,_j 
(fimole*day/L) p=0.0001
91“ 58-138 92* 58-150 55b 47-65 57b 54-92
TCF NOj' AUC.,^7  
(pmole*day/L) p=0 .0001
152' 98-196 147* 98 - 203 95b 87 -105 101b 94-132
Those treatment medians with different sapencripts, within a parameter, are significantly different at the p £ 0.0S level. Those parameters with 
medians witboat sapencripts had no significant differences upon multiple comparison. The p values shown with the parameters is the value 
obtained from the Friedman's test. NaCI-N = saline treatment non-inflamed; NaCI-I = saline treatment inflamed; CIM = cimetidine treatment; 
AG = aminoguanidine treatment; AUC -  area under the curve; TCF = tissue chamber fluid. NaCI-N and NaCI-I correspond to Treatment 1. 
There were no control chambers sampled during Treatments 2 & 3.
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NaCI-N 1 NaCl-1 C1M AG
Parameter median range median range median range median range
TCF neutrophils AUC.|_»j 
(K*day/|iL) p=0.0023
8 .6 * 7.6-510 I31b 87-521 781,b 27-183 157b 65-670
TCF neutrophils AUC.|_ ,7 
(K*day/|iL) p=0.0079
39 . 12-878 236b 114-972 100*b 66-470 2991 82- 1299
TCF % neutrophils AUC.i-o 
(%»day) p=0.0114
249* 176-357 328b 275 - 366 310b 220 - 369 355b 248 - 378
TCF % neutrophils AUC.i_»7 
(%*day) p=0.0079
499* 320-725 692*b 518-733 628b 484 - 744 691b 502-756
TCF lymphocytes AUC.|_»i 
(K*day/pL) p=0.0390
2 .6*’l> 1.3-12 1.8^ 0.82 - 1 0 1.8* 0.72-6.3 5.6b 0.99-11
TCF % lymphocytes AUC.j_»j 
(%«day) p=0.0492
79 14-98 26 15-36 37 15-53 19 7.9-87
TCF % lymphocytes AUC.|_ ,7 
(%»day) p=0.0079
171* 28-260 47b 23-87 75** 24-126 53b 13-126
TCF % monocytes AUC.,_o 
(%»day) p=0.0044
55* 28-123 40b 18-90 36b 16-113 25k 14-47
blood % lymphocytes AUC. |_ ,7 
(%«day) p=0.0478
• • 224 136-329 248 200 - 301 241 172-334
blood basophils AUC.i_,3 
(K*day/pL) p=0.0001
- - 0.17* 0.050-0.46 0.17* 0.017-0.33 0.050b 0 - 0 .1 2
blood % basophils AUC.1^3 
(%«day) p=0 .0001
• • 1.7* 0.50-4.6 1.7* 0.17-3.3 0.50b 0 - 1.2
Those treatment medians with different saperscripts, within a parameter, are significantly different at the p £ 0.0S level. Those parameters with 
medians withont saperscripts had no significant differences upon multiple comparison. The p values shown with the parameters is the value 
obtained from the Friedman’s test. NaCl-N = saline treatment non-inflamed; NaCI-I = saline treatment inflamed; C1M = cimetidine treatment; 
AG = aminoguanidine treatment; AUC = area under the curve; TCF = tissue chamber fluid; K = 1,000 cells. NaCI-N and NaCI-I correspond to 
Treatment 1. There were no control chambers sampled during Treatments 2 & 3.
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Figure 3.4. Mean (±SD) TCF neutrophil concentrations following NaCL, CIM, or AG 
treatment in Trial 1. NaCl, CIM (3 mg/kg), or AG (25 mg/kg) were administered at -1, 
-0.5 and 0 days.
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3.5. Mean (±SD) TCF monocyte concentrations following NaCl, CIM, or AG 
treatment in Trial 1. NaCl, CIM (3 mg/kg), or AG (25 mg/lcg) were administered at -1, 
•0.5 and 0 days.
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Figure 3.6. Mean (±SD) TCF lymphocyte concentrations following NaCl, CIM, or AG 
treatment in Trial 1. NaCl, CIM (3 mg/kg), or AG (25 mg/kg) were administered at -1, 
-0.5 and 0 days.
treatment It should be noted that the percentage lymphocytes in the control chamber measured 
as AUC. , - 7  were, however, higher than in the test chamber during the NaCl treatment period, 
and the same was true for monocytes measured as AUC.[_3. Concentrations of basophils were 
reduced by AG but not by CIM in blood, compared with NaCl treatment This was also 
accompanied by a decrease in the percentage of blood cells which were basophils.
Total protein and albumin: Total protein and albumin concentrations were measured in 
plasma and TCF to assess the degree to which tissue microvasculature increased in porosity. 
The only value which was significant at the p < 0.05 level was Friedman’s test for TCF total 
protein AUC-i_»3 values (Table 3.4). There was no indication, however, that inflammation 
increased either albumin or total protein concentrations in the test chamber compared to the 
control. Likewise, neither CIM nor AG had any effect on either parameter either in test 
chamber or in plasma.
Cytokines: The mean values for TNF-ct, IL-1, and IL-6  in TCF are shown in Figures 
3.7, 3.8, and 3.9, respectively. The values for all cytokines peaked between 0.5 and 1 day post-
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inflammation in TCF. Cimetidine treatment appeared to have a greater response than the NaCl- 
I treatment There were no significant differences between values in any of the cytokines 
following treatment None of the cytokines were detected in plasma at any time point in any of 
the treatment groups. Interleukin-1 activity peaked twice in inflamed TCF following NaCl 
treatment (Figure 3.8). Following inflammation in the NaCI-I group, IL- 6  activity also had a 
double peak (Figure 3.9). The secondary increase appears to follow the infiltration of 
leukocytes into the inflamed chambers with the primary response associated with resident 
leukocytes (Figures 3.4, 5, and 6 ).
Data were also analyzed as AUC of TNF-a, IL-1, & IL- 6  concentrations from -1 day 
to either 0.5, 1, 2 or 3 days. Those AUCs which showed a trend (0.10 £  p £  0.05) or were 
significant following the Friedman test are shown in Table 3.5. Lack o f significance at the 
earlier time points for IL-1 and 6  may be due to a lack o f sample for cytokine analysis which 
resulted in missing data points, this being especially true for the CIM treatment
PGE->: Tissue chamber fluid concentrations of PGE2 are shown in Table 3.6. Due to 
the lack of available TCF samples, statistical analysis was not conducted. There were no 
detectable PGE2 concentrations in plasma from any animal in any treatment group. This is 
consistent with results reported by Higgins & Lees (1984).
3 3 .b . Trial 2
Nitric Oxide: Mean N 03' concentrations in plasma and TCF increased markedly 
during the first 8  h following instillation of carrageenan into the test chamber, but returned to 
baseline values by 24 h (Figure 3.10). Mean values were low and variable, but less variable 
than in Trial 1, on days -2 and 1. As in Trial 1, plasma N 0 3" values paralleled those observed 
for TCF following test chamber inflammation (Table 3.7 and Figure 3.10). Comparison of N 03‘
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Table 3.4. TCF albumin and total protein AUC values from Trial I .
Parameter
NaCI-N 
median range
NaCI-I 
Median range
CIM 
median range
AG
median range
Total Protein AUC.,-, 
(g*day/dL) p=0.0642
10 9.2-12 10 8.5 -11 11 9.3 -14 12 9.9-12
Total Protein AUC.1-3 
(g*day/dL) p=0.0389
19 19-23 21 19-23 22 18-24 23 21-25
Table 3.5. Median and range of significant TCF IL-1 & IL-6  AUCs.
NaCI-N NaCI-I CIM AG
Parameter median range median range median range median range
TCF IL-1 AUC.,-, 
(U*day/mL) p=0.0960
20 17-23
n=3
101 31-307
n= 6
118 41-175
n= 6
107 72-166
n= 6
TCF IL-1 AUC.,-, 
(U*day/mL) p=0.0012
24* 5.5-73
n= 6
236b 110-805
n= 6
216b 125-468
n=3
346b 178-503
n=5
TCF IL-6  AUC.,-1  
(U»day/mL) p=0.0178
565* 261-573
n=3
383 lb 607-60639
n= 6
27511" 563-142961
n= 6
2825*" 985-14255
n= 6
TCF IL-6  AUC. , - 2 
(U*day/mL) p=0.0006
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Figure 3.7. Mean (±SD) TNF-a activity concentrations in TCF from Trial 1. NaCl, CIM (3 
mg/kg), or AG (25 mg/kg) were administered at -1, -0.5 and 0 days.
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Figure 3.8. Mean (±SD) IL-1 activity concentrations in TCF from Trial 1. NaCl, CIM (3 
mg/kg), or AG (25 mg/kg) were administered at -I, -0.5 and 0 days.
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Figure 3.9. Mean (±SD) IL- 6  activity concentrations in TCF from Trial 1. NaCl, CIM (3 
mg/kg), or AG (25 mg/kg) were administered at -1, -0.5 and 0 days.
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Figure 3.10. Mean (± SD) plasma and TCF NO3'  concentrations following NaCl and CIM 
treatment from Trial 2. NaCl or CIM ( 6  mg/kg) were administered every 8  h from -2 
to 0  days.
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Figure 3.11. Mean (± SD) plasma and TCF AG and CIM concentrations from Trials 1 and 2. 
CIM (3 mg/kg), or AG (25 mg/kg) were administered at -1, -0.5 and 0 days for Trial 1 
and CIM (6  mg/kg) was administered every 8  h from -2 to 0 days in Trial 2.
concentrations in plasma and TCF for the first 12 h after instillation o f carrageenan into the test
chamber showed that values in that chamber approximated those in both plasma and the control
chamber (Table 3.7). It is also apparent that CIM had no effect on N 0 3' formation in plasma at
4 or 8  h post-inflammation. At 12 h, however, CIM produced absolute median values which
were significantly lower than those observed following NaCl treatment. In TCF, CIM produced
a significant decrease in N 03‘ concentrations when compared to either NaCI-N chamber ( 8  and
12 h) or the NaCI-I chamber (12 h). Data were also analyzed as AUC o f N 0 3' concentrations
from -2 day to 1 (Table 3.7). Data in Table 2.4 represent only those values which were
significant (p < 0.05) using Friedman’s test for ranked AUC values. Multiple comparison
analysis did not reveal a significant difference in plasma AUC.2_»i values for CIM compared to
NaCl treatment. In TCF, AUC.2-*i values were significantly lowered by CIM treatment,
compared to NaCl. It is again notable that there was no difference in N 03* values for the test
vs. control chamber in NaCl treated animals.
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Table 3.6. TCF concentrations of PGE2 (ng/mL) after carrageenan instillation from Trial 1.
Time (days)
Treatment -1 0 0.17 0.33 0.5 1 2 3 5 7
NaCI-I <0 .1, <0 .1, <0 .1, <0.1 1.7, <0.1, <0.1 NS NS NS NS NS NS NS <0.1
NaCI-N <0 .1, <0.1 <0.1 <0.1 NS NS NS NS NS NS <0 .1, <0.1
CIM <0 .1, <0 .1, <0 .1, <0.1 0 .1, <0 .1, <0.1 NS NS NS NS 0 .1, <0.1 NS NS <0 .1, <0.1
AG <0 .1, <0 .1, <0 .1, <0.1 <0.1,0.3 NS NS 0.7 10.1 <0.1,6.3 NS 0 .2 <0.1
NS = no available samples from any animal. N= 6  and only results from available and assayed samples are reported 
Table 3.7. AUCs and concentration ofNOj' after carrageenan instillation in plasma and TCF from Trial 2.
Parameter
NaCI-N 
median range
NaCI-l 
median range
CIM 
median range
Plasma NO}' 12 h (pM)
p=0 .0 0 1 2
- - 17* <10-38 10b <1 0 - 2 2
TCF NOj 8  h (pM)
p=0.0166
2 1* 12-43 18*b <10-36 10b <10-34
TCFNOj 12h(pM) 
p=0.0009
21* <10-27 21* <10-31 10b <1 0 - 2 0
TCF NO}' AUC.2-H 
(pmole*day/L) p=0.0032
36* 30-76 38* 30-74 30b 30-58
Those treatment medians with different lettered saperscripts, within a parameter, are 
significantly different at the p^ O.OS level. The p values shown with the parameter is the 
value obtained from the Friedman’s test. NaCI-N = saline treatment non-inflamed; 
NaCI-I = saline treatment inflamed; CIM = cimetidine treatment.
3.4. DfaoMfcHi
Nitric oxide synthase is the first catalytically self-sufficient CYP to be described 
(White & Marietta, 1992). Aminoguanidine, a competitive antagonist of iNOS, presumably 
acts through interaction o f the guanidine N with the heme-iron of the porphyrin ring (Griffith & 
Gross, 1996; Griffiths, et al., 1993; White & Marietta, 1992). The active site for the binding 
of CIM to CYP is also the heme-iron moiety of the latter (Ioannoni, et al., 1986; Rendic, et al., 
1984). Fukuto and Chaudhuri (199S) suggest that the microenvironment of the heme moiety is 
different for cNOS and iNOS, which may account for the relative selectivity of antagonists for 
one or the other form. The Cys 184 residue in human eNOS, Cys 41S in rat nNOS, and Cys 
194 for murine iNOS appear to be the proximal heme ligands for L-Arg binding in the various 
isozymes (Chen, et al., 1994; McMillan & Masters, 199S). The guanidino N and the guanidino 
C of L-Arg must be in close proximity to the heme-binding ligand (Griffith & Stuehr, 199S).
Inducible NOS contains both a CYP and a reductase domain within a single 
polypeptide, thus having the properties of both CYP and CYP reductase that allow for electron 
transfer from NADPH to the heme-iron protein within one enzyme (Guengerich, 1996). It is 
not unexpected that a xenobiotic which antagonizes CYP activity by binding to the heme-iron 
containing catalytic site could also inhibit the activity o f iNOS, an enzyme with a similar active 
site. Therefore, it was logical to expect that NO derived N 03' concentrations in TCF and 
plasma would be reduced by CIM, as was anticipated for AG.
The gas, NO, has a high diffusion constant of *3300 mm2/s (Lancaster, 1997). This 
allows NO to move 0.3-0.4 mm from its site of formation by simple diffusion (Lancaster, 
1997). The biological t% of NO reported in the literature is *100 msec (Kelm & Schrader,
1990). In rats, NO is completely metabolized to NO2'  and N 03\  which is then excreted in the
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urine (Kelm Sc Yoshida, 1996). The major metabolite is N 03\  accounting for *90% of the 
excreted N following [1SN]0 administration (Kelm Sc Yoshida, 1996). Based on the molecular 
weights of N O / and NO/, it could be assumed that they are freely filtered by the kidneys and, if 
not reabsorbed, elimination would parallel glomerular filtration rate (Guyton Sc Hall, 1996). 
The finding that NO/ concentrations in plasma and control chamber TCF paralleled those in 
test chamber TCF suggests that NO was rapidly converted to N 03\  and that N O/, in turn, 
rapidly attained equilibrium between plasma and TCF. The nearly identical median 
concentrations of control chamber TCF and plasma were also probably the result of 
equilibration of NO3* between plasma and fluid of that chamber.
In the absence of 0 2, NO dissolves in H2O and is very stable. In air it will react with 
0 2 to form NO2. In HjO and plasma, NO is oxidized to NO/, which is stable for several hours. 
In whole blood, N O / and, to a much greater extent NO, are rapidly converted to N O / via a Hb 
catalyzed oxidation (Doyle & Hoekstra, 1981; Moncada & Higgs, 1993; Wennmalm, et al., 
1992). As little as 0.2 mM Hb (4% o f normal blood concentration) essentially eliminates the 
presence of NO in arterial blood (Henry Sc Singel, 19%; Lancaster, 1997) in <2 sec with 
peroxynitrite (ONOO") and/or nitrosyl Hb serving as a possible intermediates (Doyle & 
Hoekstra, 1981; Henry & Singel, 1996). The stoichiometry of L-Arg to L-citrulline to the 
formation of NO,' is 1:1:1 (Pufahl, et al., 1992; Yui, et al., 1991). Nitrate has a terminal t* of 
3.8 h in the dog (Zeballos, et al., 1995) and 4.8 h in ponies (Schneider Sc Yeary, 1975). Little 
is known about how N 03'  is handled by the kidneys. It has been assumed based on the 
molecular weights of N O / and NO3'  that plasma NO3* is freely filterable, but it has been 
postulated that the kidney may synthesize, release, and/or concentrate N O / (Grisham, et al., 
1996). Nitrate is reabsorbed preferentially over Cl' in the kidney (Greene Sc Hiatt, 1953; 
Greene & Hiatt, 1954).
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Both CIM and AG treatment resulted in a  failure of N 03' concentrations in plasma or 
test chamber to rise significantly between 4 and 12 h post-carrageenan instillation. 
Additionally, die plasma concentrations were similar to TCF concentrations at each o f the three 
time points, even though the values at 12  h were substantially lower than for either chamber 
during NaCl treatment This supports the above interpretation that NO, measured as N 03\  
equilibrates fairly rapidly between vascular and non-vascular compartments.
It is clear from this study, and others, that carrageenan stimulates the production of NO 
in inflamed tissues (Ianaro, et al., 1994; Koga, et al., 1995; Salvemini, et al., 1995; Tracey, et 
al., 1995). The above referenced reports also suggest that the increase in NO production can be 
attributed to the infiltration of leukocytes, mainly neutrophils and tissue macrophages, that 
subsequently become activated at the inflammatory site, resulting in an increase in NO 
production. Adler, et al., (1996) reported that activated macrophages are those in which iNOS 
has been induced and production of NO within the cell has increased. This increase is believed 
to be partly due to NO itself as it can act both as an inhibitor and activator of COX (Di Rosa, 
et al., 1996; Imai, et al., 1993; Salvemini, et al., 1993; Salvemini, et al., 1995). A product of 
COX, PGE2, can in turn act as a stimulator o f iNOS synthesis. This also applies to various 
pro-inflammatory cytokines, such as IL-1 (3 and TNF-cl These compounds can be formed as 
part of an inflammatory response and start a pro-inflammatory cytokine cascade, which also 
stimulates the production of NO (Ianaro, et al., 1994). These three pro-inflammatory agents 
are known to both induce and inhibit various isoforms of CYP (Kudo & Kawano, 1999; 
Morgan, 1997; Sewer, et al., 1996; Sewer & Morgan, 1997). These CYP proteins may be 
metabolizing L-Arg to NO and L-chrulline in this carrageenan inflammation model. It is 
unknown if the concentrations of PGE2, TNF-a, IL-1, and IL-6  produced in the TCF o f this
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study are sufficient to induce CYP isofbnns, but this possibility cannot be discarded as a 
possible explanation of the source of N 03‘ and the reduction o f N 03' be CIM and AG.
The presence of membrane bound Hr receptors on leukocytes has been previously 
reported (Tasaka, et al., 1992; Vaimier, et al., 1991). It is possible that iNOS could be coupled 
to membrane bound Hrreceptors on leukocytes, similar to the mechanism by which IL-6  
synthesis and receptor expression is altered (Mer&ey, et al., 1991; Vannier & Dinarello, 1994) 
or increases IL-13 mRNA levels (Vannier & Dinarello, 1993). If NO production were 
regulated by an Hrreceptor mechanism, then administration o f HIS would cause an increase in 
NO production or iNOS mRNA synthesis. Histamine regulates the formation of many pro- 
inflammatory mediators (Auer, et al., 1991; Rezai, et al., 1990; Vannier, et al., 1991), so it 
would not be surprising if it had a role in regulating NO production (Kelm, et al., 1993; 
Mannaioni, et al., 1997).
There is no documented interaction of either L-Arg or AG with Hrreceptors. It is 
possible, however, to hypothesize that since CIM binds to these receptors (Brimblecombe, et 
al., 1978), a similar guanidine-like compound such as AG could also interact. If so, then it 
could also be possible for AG or CIM to be internalized through interaction with the receptor, 
allowing for transport of the compound across the membrane and into the cytosolic space, 
where it could interact with iNOS.
The NO produced in response to carrageenan is attributed mainly to neutrophils and 
macrophages (Ianaro, et al., 1994; Koga, et al., 199S; Salvemini, et al., 1995; Tracey, et al., 
1995). In all o f these studies, the production of NO or the induction of iNOS mRNA reached 
maximum levels at 12 h post stimulation. One study that employed immunohistochemical 
staining for iNOS, showed that most o f the activity was associated with tissue macrophages
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(Salvemini, et al., 1995). In Trial 1, the increase in N 03* production paralleled the influx of 
neutrophils into the chamber (Tables 3.2 & 3.3).
The presence o f high NCV concentrations on day -1 in Trial I was unexpected. The 
treatment portion of this study was begun in the month of October. The Bahia grass pasture 
that the animals were held in immediately prior to the first treatment was still growing, and at 
approximately two weeks before the start o f the study it had been fertilized with 91 kg/acre of 
urea. Urea is known to be taken up by plants and converted to N H / and then to N 03‘ for 
storage and later use as a N source (Pilbeam & Kirkby, 1990). Since all animals received the 
NaCl treatment first and closest in time to the urea treatment of the grass, it is possible that 
elevated concentrations of N 03‘ on day -1 are due to N 03' concentrations in the grass. As the 
study progressed and less fresh grass was available, the -1 day N 03' concentrations decreased, 
coincident with AG and CIM treatment This is the only time a N source was applied to the 
pasture during the course of the study and offers a plausible explanation of the results observed 
on day -1. Additionally, the animals were maintained in a stall bam and fed only pelleted feed 
during the treatment and sampling period. The plasma t<* of N 03' following IV administration 
of NaN02 has been estimated at *4.8 h in pomes (Schneider & Yeary, 1975). Thus it would 
not be surprising to find that while N 03' concentrations were variable and somewhat high at day 
-1, they declined substantially by day 0 in both plasma and TCF. This problem was avoided in 
the design of Trial 2 by holding the animals in non-bedded stalls and feeding only pelleted feed 
for two weeks before initiation of the study.
It is possible that the lack of a parallel reduction in TNF-a, IL-1, & IL-6  production 
with N 03‘ prior to day 3 of the study may be due to the regulation of iNOS. For induction of 
iNOS, pro-inflammatory cytokines must first be produced. Once this takes place and results in 
increased NO production, the resulting increase in NO causes a positive feedback to increase
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TNF-a, IL-1, & IL-6  production. Even with CIM and AG pretreatment, the resulting decrease 
in NO production appears to be too late to decrease the early cytokine response. However, it 
may assist in preventing the NO-induced up-regulation of p ro  inflammatory cytokine 
production.
The expected result of CIM treatment decreasing IL-1 and IL-6  production (Vannier & 
Dinarello, 1993; Vannier & Dinarello, 1994) was not observed in this study. While there was 
no significant difference between the AUCs of IL-1 or IL-6  in NaCI-N TCF vs. CIM TCF, the 
CIM treatment was also not different from the inflamed TCF. It is possible that this is a result 
of the dosage regimen used in Trial 1. This could have resulted in sub-efficacious 
concentrations o f CIM present in TCF and the inability of CIM to inhibit IL-1 and IL-6  
production to a level that would be statistically significant
In conclusion, CIM, an H2-receptor antagonist used to treat and prevent gastric 
ulceration, is effective in inhibiting inflammation generated NO associated NO3'  concentrations. 
This could occur via the same mechanism of heme-iron binding that CIM employs to inhibit 
CYP mediated metabolism. The effect could also be at least partially attributed to an 
interaction at H2-receptors on leukocytes or macrophages. This finding brings focus to; 1) the 
potential effect o f similar H2-receptor antagonists on inflammation related NO production; 2) 
the possibility that other guanidine moiety containing substances may affect NO production; 3) 
the question of whether CIM or other H2-receptor antagonists inhibit constitutive NOS isoforms 
and therefore affect physiologic processes other than inflammation, and finally 4) the possibility 
that the reduction in gastric acid production produced by p recep to r antagonists is in fact 
mediated partially through a reduction in local NO production.
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may assist in preventing the NO-induced up-regulation of pro-inflammatory cytokine 
production.
The expected result o f CIM treatment decreasing IL-1 and IL- 6  production (Vannier & 
Dinarello, 1993; Vannier & Dinarello, 1994) was not observed in this study. While there was 
no significant difference between the AUCs o f IL-1 or IL-6  in NaCI-N TCF vs. CIM TCF, the 
CIM treatment was also not different from the inflamed TCF. It is possible that this is a result 
o f the dosage regimen used in Trial 1. This could have resulted in sub-efficacious 
concentrations of CIM present in TCF and the inability o f CIM to inhibit IL-1 and IL-6  
production to a level that would be statistically significant
In conclusion, CIM, an Hr-receptor antagonist used to treat and prevent gastric 
ulceration, is effective in inhibiting inflammation generated NO associated N 03' concentrations. 
This could occur via the same mechanism of heme-iron binding that CIM employs to inhibit 
CYP mediated metabolism. The effect could also be at least partially attributed to an 
interaction at Hrreceptors on leukocytes or macrophages. This finding brings focus to; 1) the 
potential effect o f similar H^receptor antagonists on inflammation related NO production; 2) 
the possibility that other guanidine moiety containing substances may affect NO production; 3) 
the question o f whether CIM or other Hz-receptor antagonists inhibit constitutive NOS isoforms 
and therefore affect physiologic processes other than inflammation, and finally 4) the possibility 
that the reduction in gastric acid production produced by Hz-receptor antagonists is in fact 
mediated partially through a reduction in local NO production.
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CHAPTER 4  -  MECHANISM OF CIMETTDINE AND AM INOGUANIDINE 
INTERACTION W ITH HEPATIC M ICROSOM ES AND EQUINE LEUKOCYTE 
PROTEIN
4.1. Iutrod action
All isoforms of NOS are homodimcrs with a molecular weight of *300 kDa (Yui, et 
al., 1991), which contain a heme-iron protein with binding sites for the following co­
substrates/cofactors: O2, NADPH, FAD, FMN, (Stuehr A  Ikeda-Saito, 1992), L-Arg, and 
THB (Di Rosa, et al., 1996; Fukuto A  Chaudhuri, 1993; Gross A  Levi, 1992). The normal 
endogenous concentration of L-Arg is between 100 and 800 mM with iNOS having a Kn, o f *17 
HM (HeveL, et al., 1991; Frey, etal., 1994). Inducible NOS formation is regulated primarily by 
induction of NOS protein synthesis at the transcription level via several cytokines, such as 
TNF-a, INF-y, and IL-13 (Adler, et al., 1995; de Vera, et al., 1996; Geller, et al., 1993; 
Spink, etal., 1995).
Cimetidine is a proven inhibitor o f CYP (Ioannoni, et al., 1986; Rendic, et al., 1984). 
Farup, et al. (1988) mentions that this effect is also observed after IV administration o f RAN. 
The inhibition o f CYP is mediated through this heme containing protein by binding to 
structurally similar H2-antagonists as a 6 * axial ligand with Fe, and CIM having the lowest KD 
(Rendic, et al., 1983). This binding results in a Type II optical difference spectrum (Lin A  Lu,
1998; Schenkman, et al., 1967) associated with the direct binding of CIM to the heme moiety of 
CYP. Both the cyano and imidazole groups of CIM have been shown to bind to the heme-iron 
at the 6 th axial position (Rendic, et al., 1983). Cimetidine is known to inhibit CYP 2C6 and 
2C11 in vitro and in vivo (Levine, et al., 1998). Cimetidine does not interact with all heme- 
containing proteins as it has been shown not to form a 6 * axial ligand on the heme-iron of 
mouse catalase (Baird, et al., 1987).
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Several different experiments were undertaken in the following sequence. The first 
group of experiments were conducted to determine if AG, HIS, and the Hrantagonists (CIM, 
RAN, or ZAL) alter the spin state of the Fe in the heme-iron proteins CYP and iNOS. 
Cimetidine binding to CYP results in a Type fi optical difference spectrum (Lin & Lu, 1998; 
Schenkman, et al., 1967) associated with the direct binding o f CIM to the heme moiety of CYP. 
The binding of L-Arg to NOS results in a Type I spectra and is similar to the spectra obtained 
from CYP after binding o f various substrates and suggests that L-Arg is altering the heme 
microenvironment of NOS (Kerwin, et al., 199S). The method o f McMillan, et al. (1992) was 
used to determine whether Type I or Type II binding spectra were associated with the binding of 
CIM, RAN, ZAL, HIS, and AG to iNOS in equine leukocytes collected from tissue chambers. 
If any of these compounds produce a Type I difference spectra, this would indicate that binding 
was taking place at a hydrophobic site in the protein near the heme iron, thus altering the heme 
microenvironment of CYP and/or NOS. If a Type II difference spectra is observed, then these 
ligands are interacting directly with the heme iron at the 6 * axial position (Alvares & Pratt, 
1990). Additional experiments were conducted to determine if spectral changes occurred with 
CIM in the presence of equine Hb, and the effect of CIM on the conversion of NO to N0 3\  
This was done in an attempt to specifically determine where in the metabolism of L-Arg to N 03' 
CIM was inhibiting the formation of N 03‘. Hemoglobin is necessary for the conversion of NO 
to N 03‘ (Doyle & Hoekstra, 1981; Moncada & Higgs, 1993; Wennmalm, et al., 1992) and as a 
heme-containing protein, may be bound by CIM resulting in decreases in N 03' production. The 
following spectral studies were conducted in order to confirm that CIM would produce a Type 
II binding spectra when added to hepatic microsomes, and to provide basic data about the 
difference spectra produced by RAN, ZAL, HIS, and AG with hepatic microsomes.
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4.2. Materials & Methods 
4.2 .a. Experiment 1
Two male rats from the LSU Department of Laboratory Animal Medicine was 
euthanized with C 02. The livers were immediately removed and flushed with *200 mL of 
chilled (*4°C) physiological buffered NaCl (PBS). They were homogenized using a chilled 
(*4°C) teflon pestle and glass tube in 2 volumes (*40 mL) of 0.5 M K2H P04 (pH 7.2). The 
resulting suspension was then centrifuged at 9,000 xg  for 20 min (S°C). The supernatant was 
then centrifuged for one h at 110,000 xg  (S°C). The supernatant was removed and the pellet 
resuspended in an equal volume of 0.1 M 4-(2-hydroxyethyl)-1 -piperazine-ethanesulfonic acid 
(HEPES) buffer (pH 7.2) using a one mL syringe with a 25 gauge needle. The suspension was 
again centrifuged for one h at 110,000 xg  (5°C), the supernatant removed and the pellet 
resuspended in 0.1 M HEPES as above.
Total protein was determined using a commercially available assay (Micro Protein 
Determination, Sigma Diagnostics, St. Louis, MO). Fifty pL of standard or sample was added 
to 2.5 mL o f diluted (1:4) protein dye reagent (Coomassie blue) and incubated for 2 min. The 
samples were then placed in a spectrophotometer (U-3010, Hitachi Instruments, Ltd., Tokyo, 
Japan), and absorbance was measured at X=595 nm. Linear regression analysis was performed 
on the standards to obtain a regression equation and quantitate unknowns. All standards and 
unknowns were assayed in duplicate.
Carbon monoxide (CO) difference spectra were also obtained as described by Omura & 
Sato (1964). Three mL of hepatic microsome suspension had CO bubbled through for 30 sec. 
One mL disposable cuvettes were used for all scans. A one mL sample was then scanned using 
a UV/VTS scanning spectrophotometer over the range of 350-500 nm, in triplicate. Dithionite 
was added and the scan repeated. The resulting scans were subtracted from each other to yield
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a difference spectra with a peak at 4S0 nm. The absorbance o f this peak was used to calculated 
the amount of CYP in the sample (Omura St Sato, 1964).
Difference spectra were obtained using a 1 mg/mL suspension of the rat hepatic 
microsome preparation for CIM, RAN, ZAL, HIS, AG, L-Arg, and hexobarbital (HEX) at 0, 
0.05, 0.1, 0.2, 0.5, 1.0, and 1.5 mM. Samples were scanned over the range of 390 -  500 nm, 
except AG and HEX which were scanned from 350 -  500 nm.
4.2.b F.th>Hm « » 2
A second, similar, experiment was conducted on equine hepatic microsomes. These 
studies were used to verify that equine hepatic microsomes produce difference spectra similar to 
those produce by the rat and to also allow tor comparison between equine CYP difference 
spectra and equine iNOS difference spectra. One pony from the LSU herd was euthanized by 
electrocution and exsanguinetion. The liver was immediately removed and an *200 g piece was 
cut and flushed with *1.5 L of PBS (*4°C). The tissue was then cut into *20 g pieces and 
further minced for homogenization and centrifugation as described in Experiment 1. Upon 
completion of the second 1 1 0 ,0 0 0  xg centrifugation, the supernatant was removed and a layer 
o f glycerol was placed over the pellet and frozen at -70°C until needed.
Total protein and CYP content were determined as described above. Difference spectra 
were obtained using a 1 mg/mL (protein) equine hepatic microsome suspension for CIM (0, 
0.05, 0.1, 0.2, 0.5, 1.0, and 1.5 mM), RAN (1, 2, 5, 7.5, and 10 mM), HIS (0.5, 1.0, 2.0, 5.0, 
and 10 mM), AG (0.5, 1.0, 2.0, 5.0, and 10 mM), and HEX at 0, 0.05, 0.1, 0.2, 0.5, 1.0, and 
1.5 mM.
4.2.C ExgfriqK Tt?
To demonstrate that CIM was possibly inhibiting iNOS by a mechanism similar to that 
by which CIM inhibits CYP, difference spectra were
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obtained in the following experiment from leukocytes following carrageenan-induced 
inflammation.
Animals: Six female Thoroughbred horses belonging to the Equine Veterinary
Research Program herd, and ranging in age from 10-18 years and 468-523 kg, were used in this 
study. All animals were part of a routine health maintenance program and were clinically 
healthy. They were fed only pelleted feed, and water was available ad libitum. The research 
protocol was approved by the LSU Institutional Animal Care and Use Committee prior to 
initiation o f the study. These were the same horses as those used in the previous studies 
(Chapter 3).
Inflammation and sample collection: To induce inflammation, one mL of 1% sterile 
carrageenan (X-carrageenan; Sigma Chemical Co., S t Louis, MO) was instilled into a chamber. 
Tissue chamber fluid from the inflamed chamber was collected at 8  h post-instillation. Samples 
(10 to 20 mL) o f TCF were collected under aseptic conditions and transferred immediately to 7 
mL EDTA containing evacuated tubes, and placed on ice. The leukocytes were then separated 
using a gradient technique (Leukocyte separation, Sigma Diagnostics, S t Louis, MO). Briefly, 
3 mL of a 1.119 g/mL solution of polysucrose and Na diatrizoate (Histoplaque*-l 119, Sigma 
Diagnostics, S t Louis, MO) was placed in a 15 mL conical centrifuge tube. Next, 3 mL o f a 
1.077 g/mL solution of polysucrose and Na diatrizoate (Histoplaque®-1077, Sigma 
Diagnostics, S t Louis, MO) was placed on top o f the previous solution in a manner such that 
little or no mixing occurred. Six mL o f TCF was then pipetted onto these solutions and the tube 
was centrifuged at 700 xg  for 30 min (*25°C). The tubes were then removed and the two 
separate layers o f mononuclear cells and granulocyte cells were aspirated and transferred to a 
single clean tube. Ten mL o f PBS was then added to each tube and centrifuged for 10 min at
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200 xg («2S°C). The supernatant was decanted and the leukocytes were stored in one volume 
o f  0.1 M HEPES at -70°C until needed.
Cells were homogenized using a rapid decompression method (Short, et al., 1972). The 
sample, in a SO mL conical centrifuge tube, was placed in a cell disruption bomb (Parr 
Instruments). Using N& 5200 kPa was applied for S min. The outlet valve was then opened 
and the sample collected into a clean centrifuge tube. The sample was centrifuged for 1 h at
110,000 xg. The resulting supernatant was used for all subsequent studies.
Carbon monoxide difference spectra were conducted using both dithionite and NADPH 
as the reducing agents. Total protein was determined as previously described. Difference 
spectra were obtained using a 1 mg/mL (protein) equine leukocyte (LEUK) suspension for CIM 
(0, 0.05, 0.1, 0.2, 0.5, 1.0, and l.S mM), HIS (0.5, 1.0, 2.0, 5.0, and 10 mM), AG (0.5, 1.0, 
2.0, 5.0, and 10 mM), and HEX at 0, 0.05, 0.1, 0.2, 0.5, 1.0, and 1.5 mM.
4.2.d. f  i  ’ al 1
Using an aliquot of the preparations made in Experiments 2, 3, and a preparation from 
leukocytes collected from horses injected with LPS, electrophoresis and Western blots were 
conducted to confirm the presence o f iNOS in equine leukocytes and determine if  iNOS was 
present in the equine hepatic microsome preparation.
Sodium dodecylsulfate (SDS) separating gels, 7.5%, were used under denaturing 
conditions. The separating gel consisted of 7.5 mL deionized HiO, 3.75 mL of 1.5 m  
tris(hydroxymethyl)aminomethane (Tris) buffer (pH 8 .8 ), 3.75 mL of 30 % acrylamide, and 
150 pL of 10% SDS. This solution was gently mixed and degassed. Ten pL o f N,N,N',N'- 
tetramethyl-ethylenediamine (TEMED) and 50 pL o f 10% ammonium persulfate (APS) were 
added to the solution which was then covered with 100 pL butanol. The stacking gel was as 
follows: 3 mL of deionized H2 0 , 1.25 mL 0.5 M Tris buffer (pH 6 .8), 650 pL 30% acrylamide,
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and SO 10% SDS. The solution was mixed and degassed Five |JL of TEMED and 25 pL 
of 10% APS were added to the solution and the gel was poured.
For analysis, 24 pL o f Sigma molecular weight standards were placed in lanes 1 and 10 
of the gel. One pL of murine iNOS standard (Cayman Chemical Co., Ann Arbor, Michigan), 
19 pL of buffer (SO mM Tris, 1S.S mM NaCl), and 4 pL of 6 x loading buffer were placed in 
lanes 2 and 9. Twenty pL of the iNOS preparation (Experiment 3) were added to lane 3 along 
with 4 pL o f 6 x loading buffer. Lane 4 was used for the equine hepatic mkrosome preparation 
from Experiment 2. Twenty pL of the equine hepatic mkrosome prep were placed in lane 4 
along with 4 pL o f 6 x loading buffer. All samples had been boiled at 100°C for S min prior to 
loading on to the gel. The gel was nm for 2 h at 100 mV. Gels were transferred using a wet 
transfer technique (BioRad Electroblot, BioRad, Hercules, CA) at 4°C. The gel was stained 
with rapid Coomassie blue for 20 min in a 25% isopropanol/10% acetk acid solution. It 
appeared that the molecular weight markers completely transferred.
Western blots were conducted using a PVDF transfer membrane (Hybond P, 
Amersham Life Sciences, Arlington Heights, IL). The membrane was rinsed in Tris buffered 
NaCl (TBS-T; 2.43 g Tris, 8.0 g NaCl, 3.8 mL 1.0 M HC1, 0.1 % Tween"* 20, and HjO to one 
L) and the transfer was done in the presence of TBS-T with 5% dry milk added. The membrane 
was then rinsed again for 2 min (2x). The blot was incubated for 1 h with the primary 
antibody, which is a mouse monoclonal to the C-terminus region (amino acids 961 -  1144) of 
the murine iNOS monomer (Transduction Laboratories, Franklin Lakes, NJ) using a dilution of
1200,000 of the stock 2S0 pg/pL solution. The membrane was then washed for S min (9x) 
with TBS-T using 60 mL/rinse. The membrane was incubated with the secondary antibody 
complexed to horseradish peroxidase (donkey anti-rabbit, Amersham Pharmacia, Arlington 
Heights, Illinois) for 1 h and then washed for S min (9 x) with TBS-T using 60 mL/rinse. The
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iNOS protein was detected using a chemilumincscent system (ECL+Plus, Amersham Pharmacia 
Biotech, Arlington Heights, IL). Detection was accomplished following the instructions 
accompanying the kit at «2S°C with incubation o f membrane and detection reagents for S min.
A second blot, based on the results o f the first, was also run. This blot was run in the 
presence of the protease inhibitors dithioreitol, leupeptin, and phenyhnethylsulphonyl fluoride at 
final concentrations o f 1 mM, 10 pg/mL, and 10 mg/mL, respectively (Knowles & Salter, 1998) 
to reduce the possibility o f enzyme degradation in the samples. These were added immediately 
prior to cell homogenization and the homogenate was frozen at -70°C until needed. Three 
horses were used, and cells collected from all available chambers prior to inflammation. The 
next day, one chamber in each horse was inflamed with 1 mL of 1% carrageenan and TCF was 
collected at 8  h post inflammation. All analysis conditions were the same as above.
A third blot was also performed. This blot was done using circulating leukocytes 
collected from a horse at 0 and 4 h after a single, 30 minute infusion o f LPS (35 ng/kg). The 
cells were separated and prepared, in the presence of protease inhibitors, as described in 
Experiment 3. The cell homogenate was frozen at -70°C until needed. All analysis conditions 
were the same as above.
4.2.e. Experiments
This experiment was conducted to determine if  spectral changes occurred with CIM in 
the presence o f equine Hb. Hemoglobin is necessary for the conversion o f NO to N 03' (Doyle 
& Hoekstra, 1981; Moncada & Higgs, 1993; Wennmalm, et al., 1992) and as a heme- 
containing protein, may bind to CIM and result in decreases in N 03‘ production. This 
experiment was conducted using die methods described in Experiments 1 - 3 .  Equine Hb 
(Sigma Chemical Company, S t Louis, MO) was used at concentrations o f 0.1 and 1 mg/mL in 
PBS. Cimetidine was added to the sample cuvette to yield final concentrations o f 0, 0.1, 0.5,
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and 1.0 mM. Zahidine interaction was also investigated at concentrations of 0, 1, 5, and 10
mM.
4.2. fl Ftnt riant n l 6
This study was conducted in an attempt to specifically determine where in the 
metabolism of L-Arg to N O / CIM was inhibiting the formation of N 03\  Hemoglobin is 
necessary for the conversion o f NO to NOa' (Doyle A  Hoekstra, 1981; Moncada A  Higgs, 
1993; Wennmalm, et al., 1992) and as a heme-containing protein, may bind to CIM and result 
in decreases in NO3'  production. Based on the results o f Experiment 5, studies were conducted 
to evaluate the ability o f CIM to inhibit the conversion o f NO to N O /. The effect of CIM on 
the conversion o f NO to N O / catalyzed tty Hb was investigated using a carbon fiber 
microsensor to detect NO (ISO-NOP30, World Precision Instruments, Inc., Sarasota, FL).
The microsensor was connected to an isolated NO meter (ISO-NO, World Precision 
Instruments, Inc., Sarasota, FL) which was serially connected to a personal computer using an 
18-bit data recording system (Duo* 18™, World Precision Instruments, Inc., Sarasota, FL). All 
studies were conducted at 37°C. The microsensor was calibrated using SNAP (Figure 4.1). A 
stock solution o f SNAP was prepared each day that studies were conducted. Fifty mg of EDTA 
was added to 250 mL o f H2O (pH 9.0). Approximately 5 mg o f SNAP was added to the EDTA 
solution and the molarity o f SNAP calculated. Next, 10 mL of 0.1 M CUSO4 (pH 4.0) was 
pipetted into a 20 mL scintillation vial and placed in a  H2O bath. The microsensor was placed 
in the solution and allowed to equilibrate. A baseline reading was obtained and then 10, 20, 40, 
and 80 pL of the SNAP solution was added and the current (pA) recorded after each addition. 
This was repeated twice to obtain a standard curve for NO determination.
Since SNAP requires sub-physiological pH (*4) and CuS04 as a catalyst to produce 
NO, it was not appropriate for generating NO at physiological conditions. For these reasons
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diethylamine (DEA/NO; Figure 4.1) was used as a NO source as it spontaneously degrades to 
NO at physiological pH (7.4) in PBS. The first experiment was done using 10 mL of PBS to 
which 50 pL of a 0.3 mg/mL solution (pH 9.0) o f DEA/NO was added. Nitric oxide 
production was measured for 10 minutes and 100 pL aliquots were removed every 2 minutes 
and placed in 100 pL of 10% TCA and frozen at -70°C for N 03~ analysis. This was done in 
triplicate. Next, CIM was added to a final concentration of 1.5 mM to determine if CIM 
effected the production of NO from DEA/NO. An additional group o f studies were done in the 
same manner, except that a 1 mg/mL solution of equine Hb (*0.015 mM) in PBS was used. 
Cimetidine was added to the solution to give final concentrations o f 0, 0.1, 0.5, 1.0, and 1.5 
mM. Nitrate analysis was conducted using the method described in Chapter 3.
Figure 4.1. Structure o f  S-nitroso-W -acetyl-D .L-penicillam ine (SNAP) and diethylamine
(DEA/NO).
43 . Results 
4J jl Experiment 1
The Hz-antagonists produced varying responses when incubated with the rat hepatic 
microsome preparation (1 mg/mL protein; 0.3pM CYP/mg protein). For CIM (Figure 4.2), 
classical Type II spectra (Alvares & Pratt, 1990) similar to those previously reported (Pelkonen
SNAP
N -N
N -O
0*3 DEA/NO
8 6
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& Puurunen, 1980; Rendk, et al., 1983; Rendk, et al., 1984) were observed at concentrations 
sO.l mM. Ranitidine (Figure 4.3) produced neither Type I nor II spectra at the concentrations 
tested, which is similar to published reports (Rendk, et al., 1983; Rendk, et al., 1984). 
Zahidine’s difference spectra (Figure 4.4), at the concentrations evaluated, did not produce an 
identifiable Type I or II spectra, but did show concentration dependent spectral changes. 
Histamine (Figure 4.S) produced a classic Type II difference spectra, indicating that it was 
interacting with the heme iron of CYP (Alvares & Pratt, 1990). Aminoguandine (Figure 4.6) 
yielded a Type I spectra similar to HEX (Figure 4.7), which is known to produce a Type I 
difference spectra. L-Arginine did not yield a spectra that changed across the range of 
concentrations studied. This is different from previous results with the NOSs (Abu-Soud, et 
al., 1994; Kerwin, et al., 1995) that showed L-Arg produced a Type I spectra in rat nNOS, 
iNOS, and CYP. The lack of a Type I spectra with L-Arg in the current rat hepatic mkrosomes 
is probably due to the different concentrations o f L-Arg used in the different experiments. The 
previous work used concentrations reflecting extracellular values (100 - 800 mM), were the 
above study used concentrations over the range o f 0.5 -  1.5 mM, identical to the concentrations 
used for CIM spectral analysis.
4_3.b. Experiment 2
The data from equine hepatic mkrosomes were similar to die rat hepatk mkrosome results 
above. For CIM (Figure 4.8), there was a change in the absorbance taking place, which 
appeared to be a  Type II difference spectra. The characteristk peak at *440 ran is not easily 
seen following the addition of CIM as a result of the large trough at *420 nm, but the 440 ran 
CIM peak was o f the same order of magnitude as the 440 nm peak following HIS addition to 
the equine hepatk mkrosomes. Ranitidine did not show either a Type I or Type II spectra 
across the range of concentrations tested. This is similar to reports previously published
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(Rendk, et al., 1983; Rendk, et al., 1984). Histamine (Figure 4.9) addition to the equine 
hepatic microsome preparation yielded a classic Type II difference spectra, similar to that 
shown in Experiment 1 above, and reported by Brandes and cowcfkers (1998).
Aminoguanidine, as in the rat hepatic mkrosomes, yielded a Type I binding spectra 
(Figure 4.10) and is similar to the HEX spectra in equine hepatk mkrosomes (Figure 4.11). A 
Type I spectrum is indicative o f an interaction with a hydrophobk she near the heme iron rather 
than a direct interaction with the heme iron (Alvares & Pratt, 1990).
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0 .0 0 0
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- 0.010
CIM 0.06 mM 
CIM 0.1 mM 
CIM 0.2 mM 
CIM 0.5 mM 
CIM 1.0 mM 
CIM 1.5 mM
-0.015
- 0.020
-0.025
Figure 4.2. The Type II difference spectra for concentrations o f cimetidine in rat hepatic 
mkrosomes.
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Figure 43 . The difference spectra for concentrations of ranitidine in rat hepatic microsomes. 
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Figure 4.4. The difference spectra for concentrations of zattidine in rat hepatic microsomes.
89
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
0.010
0.005
0 .0 0 0
-0.005
- 0.010 HIS 0.05 mM 
HIS 0.1 mM 
HIS 0.2 mM 
HIS 0.5 mM 
HB 1.0 mM 
HB 1.5 mM
-0.015
0.020
9
-0.025
Figure 4.5. The Type II difference spectra for concentrations of histamine in rat hepatic 
microsomes.
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Figure 4.6. The difference spectra for aminoguanidine in rat hepatic microsomes.
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Figure 4.7. The difference spectra for hexobarbitai in rat hepatic microsomes.
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Figure 4.8. Difference spectra o f equine hepatic mkrosomes with various concentrations of 
cimetidine.
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Figure 4.9. The Type II difference spectra for various concentrations o f histamine in equine 
hepatic microsomes.
0.0101
0.005
0.000
-0.005
- 0.010
-0.015
-0.020
AG 0.5 mM 
AG 1.0 mM 
AG 2.5 mM 
AG 5.0 mM
-0.025
-0.030
-0.035 o
c5co co
Figure 4.10. The Type I difference spectra for various concentrations o f aminoguanidine in 
equine hepatic microsomes.
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Figure 4.11. The Type I difference spectra for hexobarbital in equine hepatic microsomes.
4.3.C. F.«wtfhM it3
A basic scan o f an equine LEUK preparation is shown in Figure 4.12 and is similar to 
that reported by McMillan and coworkers (1992). A representative CO difference spectra 
(shown in Figure 4.13), lacking a peak at *450 nm, is markedly different than previously 
reported (McMillan, et al., 1992). For CIM (Figure 4.14), there was a change in absorbance 
with a trough at *455 nm and a plateau starting at 440 nm. These spectra do not appear to be 
either a Type I or Type II CYP difference spectra. They are, however, similar to the Type II 
difference spectra generated by L-thiochrulline with nNOS (Frey, et al., 1994). Histamine 
(Figure 4.15) addition to the equine LEUK preparation yielded spectral changes across the 
range of 350-500 nm similar to those produced by CIM, but these can not be readily classified 
as either Type I or II. Aminoguanidine yielded spectra very similar to HIS (Figure 4.16) but 
they were different than the Type I spectra generated by HEX in equine LEUK preparation 
(Figure 4.17).
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Figure 4.12. Scan of equine leukocyte preparation before and after reduction with dithionite.
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Figure 4.13. Difference spectra of equine leukocyte preparation reduced with either NADPH 
or dithionite.
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Figure 4.14. Difference spectra of an equine leukocyte preparation incubated with cimetidine.
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Figure 4.15. Difference spectra for histamine in an equine leukocyte preparation.
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Figure 4.16. Difference spectra for aminoguanidine in an equine leukocyte preparation.
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Figure 4.17. Difference spectra for hexobarbital in an equine leukocyte preparation.
4 J.d . Em r ia u a t  4
Scans of the two Western blots are shown in Figures 4.18 and 4.19. In the first blot 
(Figure 4.18), no detectable band was seen for the equine hepatic tnicrosome preparation, but
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there were detectable bands in the equine LEUK preparations. These bands were not at the 
same position as the murine iNOS standard. This could be due to: 1) degradation of the iNOS 
protein by proteases and subsequent detection of iNOS protein degradation products, or 2) 
recognition of a different protein than iNOS, such as CYP or Hb. The detection of CYP is not 
likely, based on the lack o f detection o f protein in the equine hepatic mkrosome preparation in 
the lane next to the LEUK preparation. Finally, 3) it is possible that the murine iNOS antibody 
detected a different isoform of equine NOS, but this explanation is unlikely.
For the above reasons, two additional studies were conducted. The first was done in 
the presence of protease inhibitors to determine if the detected bands were degradation products. 
As seen in Figure 4.19, there was no band corresponding to the murine iNOS standard, but 
several smaller molecular weight bands were again present These were present in the samples 
taken before and after inflammation o f the chambers. These bands could be degradation 
products of iNOS, since the protease inhibitors were not added to the collected TCF until * 2  h 
after collection - after the leukocytes had been removed from the chamber and separated. It is 
also possible that they may be other unidentified proteins for which the murine iNOS antibody 
has affinity. Other possibilities are that this antibody does not have affinity for the iNOS 
isoform expressed in this equine model.
The third study was performed to determine if the method o f induction was the factor 
affecting the identification o f iNOS in equine leukocytes and if equine Hb could be detected by 
the murine iNOS antibody. Figure 4.19 indicates that following LPS treatment, equine iNOS 
could not be identified using this detection system. The murine iNOS antibody also failed to 
indicated binding to the equine Hb sample.
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Figure 4.18. Western blot of equine hepatic microtome and leukocyte preparations, without 
protease inhibitors, using a murine iNOS antibody. Equine cultured chondrocytes are 
shown as a positive control following vehicle (veh.) or lipopolysaccharide (LPS) treatment 
(trt).
To?--
v  eril ■'
i f  -
Figure 4.19. Western blot of equine leukocyte preparations (left blot), with protease inhibitors, 
prior to and 8  h after induction of inflammation using a murine iNOS antibody. Right blot 
is equine cultured chondrocytes as a positive control following vehicle (veh.) or 
lipopoly saccharide (LPS) treatment (trt)
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Figure 4.20. Western blot o f equine Hb and an equme leukocyte preparation (left blot), with 
protease inhibitors, prior to and 4 h following LPS administration using a murine iNOS 
antibody. Right blot is equine cultured chondrocytes as a positive control following vehicle 
(veh.) or lipopoly saccharide (LPS) treatment (trt.)
4J.e. Experiment S
Spectra of CIM (0.1 and 1 mg/mL Hb) and ZAL (1 mg/mL Hb) interaction with equine 
Hb are shown in Figures 4.21, 4.22, and 4.23, respectively. Cimetidine, at a concentration of
1.0 mM in 1 mg/mL Hb, produced a different spectra than observed at the lower concentrations 
for CIM, Hb or at any concentration for ZAL. This indicates that CIM interacts with Hb in 
some manner to induce a spectral change, but does not show direct interaction of CIM with the 
iron-heme of Hb or that CIM was effecting 0 2 binding to Hb.
43.C EmrrhnrnJ It
Results of this experiment are shown in Figure 4.24. The DEA/NO produced mM 
quantities of NO in PBS. Over the study period, the addition o f equine HB almost completely 
suppressed NO production and this NO production was unaffected by the addition of CIM. 
There were no detectable concentrations ofN O f in any o f the samples collected. These results 
are consistent with those previously reported. In venous blood, N O  is oxidized to NQf, which 
is stable for several hours (Henry & S ingel, 1996). In oxygenated blood, NO2' and, to a much 
greater extent NO , are rapidly converted to NO3' via a Hb catalyzed oxidation (Doyle &
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Hoekstra, 1981; Moncada A  Higgs, 1993; Wenmnalm, et al., 1992). As little as 0.2 mM Hb 
(these experiments used *0.013 mM) essentially eliminates the presence o f NO in arterial blood 
(Henry A  Singel, 1996; Lancaster, 1997) in <2 sec with ONOO' and/or nitrosyl Hb serving as 
possible intermediates (Doyle A  Hoekstra, 1981; Henry A  Singel, 1996).
4.4. Dfanmston
The 3A subfamily of CYP can convert L-Arg to L-citrulline and NO (Andronik-Lion, et al., 
1992; Boucher, et al., 1992; Schott, et al., 1994), and CYP 3A activity can be inhibited by 
CIM (Kuo, et al., 1993). This is not surprising since the NOSs are a subclass of CYP enzymes 
(Bredt, et al., 1991; Lowenstein, et al., 1992; White A  Marietta, 1992). The reaction catalyzed 
by iNOS is similar to the majority o f those catalyzed by various isoforms o f CYP, but differs in 
two ways: 1) NOS requires THB, whereas CYP does not (Rodriguez-Crespo, et al., 1996), and 
2) one o f the two products o f NOS, NO, is an odd-electron free-radical species. Typical 
products of CYP oxidation are even, two-electron products (Fukuto A  Chaudhuri, 199S). 
Inducible NOS has only been shown to produce NO and L-citrulline (Fukuto A  Chaudhuri, 
1993). There is *60% amino acid identity between CYP and iNOS (Bredt, et al., 1991; 
Lowenstein, et al., 1992; White A  Marietta, 1992). More specifically, the 10 amino acid 
sequence responsible for heme binding in CYP 3A is highly conserved between this CYP 
isoform and iNOS. Of these 10 amino acids, two are exactly the same and three others are 
functionally identical (Renaud, et al., 1993). The proximal heme ligand Cys 194 for murine 
iNOS (McMOlian A  Masters, 1993), corresponding to Cys 436 in CYP (Shimizu, et al., 1988), 
is one of the two amino acids identical in both iNOS and CYP. The similarity o f cofactors and 
binding locations within the amino acid sequence indicates that the NOS isozymes are CYP 
reductase-CYP fused hybrids (Griffith A  Stuehr, 1993; Stuehr A  Ikeda-Saito, 1992).
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Figure 4.21. The spectra of equine hemoglobin (0.1 mg/mL) interacting with cimetidine and
o 2.
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Figure 4.22. The spectra of equine hemoglobin (1 mg/mL) interacting with cimetidine and 0 2.
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Figure 4.23. The spectra of equine hemoglobin interacting with various concentrations of 
zaltidine.
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Figure 4J24. Nitric oxide production by DEA/NO in the presence of equine hemoglobin and/or 
cimetidine.
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The heme found in NOS, located in the NHz-tcrminal domain, is necessary for the 
conversion of L-OHArg to NO and L-chrulline since L-OHArg appears to bind in the proximity 
o f the heme and alters the spin state o f Fe upon binding. This results in Type I spectra and is 
similar to the spectra obtained from CYP after binding of substrates and suggests that L-Arg is 
altering the heme microenvironment o f NOS (Kerwin, et al., 1995). This was not seen with L- 
Arg in the rat hepatic mkrosome preparation used in Experiment 1, but both HEX and AG did 
produce this type of difference spectra in both rat and equine hepatic mkrosome preparations. 
Aminoguanidine is probably interacting with CYP via the guanidine moiety common to both L- 
Arg and AG. It is unclear if the binding sites far L-Arg and L-OHArg are the same (Pufahi & 
Marietta, 1993), as has been suggested (Kerwin, et al., 199S). The Cys 184 residue in human 
eNOS, Cys 415 in rat nNOS, and either Glu 371 or Cys 194 for murine iNOS appear to be the 
proximal heme ligand for L-Arg binding in the various isozymes (Chen, et al., 1994; Crane, et 
al., 1998; McMillian & Masters, 1995).
Cimetidine is a proven inhibitor o f CYP while ZAL is suspected o f this activity (Farup, 
et al., 1988; Ioannoni, et al., 1986; Rendk, et al., 1984). Farup, et al. (1988) mention that this 
effect is also observed after IV administration o f RAN, whkh contains a furan ring. Ranitidine 
did not produce a Type II difference spectra in either the rat or equine hepatic mkrosome 
experiments. The inhibition o f CYP is mediated through the heme containing protein binding to 
structurally similar Hraotagonists as a 6 * axial ligand with Fe, with CIM having the lowest KD 
(Rendk, et al., 1983). This binding results in a Type II difference spectrum (Lin & Lu, 1998; 
Schenkman, et al., 1967) associated with the direct binding of CIM to the heme moiety. Ligand 
formation is both non-competitive (Chang, et al., 1992; PeOconen & Puurunen, 1980) and 
competitive, depending on substrate concentration (Chang, et al., 1992; Winzor, et al., 1986). 
Both the cyano and imidazole groups o f CIM have been shown to bind to the heme-iron at the
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6 th axial position (Rendil, et al., 1983). This was reproduced using rat and equine hepatic 
microsomes in Experiments 1 and 2 and is consistent with the results reported by Rendid, et al. 
(1983; 1984). Classical Type II difference spectra were generated by CIM in rat and equine 
hepatic microsomes at concentrations 2 0 .1  mM. The difference spectra observed in equine 
hepatic microsomes resemble the spectral changes o f chemical oxidation reported by Hlavica, et 
al. (1989). They used 100 pM KjFe(CN)6  to oxidize rat hepatic microsomes and produced this 
unique spectra.
The Type II difference spectra o f HIS in the hepatic microsomes of both species was 
produced through the interaction of the imidazole group binding as a 6 th axial ligand (Brandes, 
et al., 1998). This interaction o f HIS with CYP isoforms is believed to also involve an 
intracellular HIS receptor located on or near the nuclei and chromatin o f bepatocytes. These 
HIS receptors appear to regulate the catalytic activity of CYP and also modulate the growth of 
normal and neoplastic cells (Brandes, et al., 1998). This may be one mechanism to explain the 
anti-tumor, anti-infective, and either pro- or anti-inflammatory properties of Hz-antagonists. 
Cimetidine and other Hz-receptor antagonists have been shown to reduce the size of equine 
melanomas (Goetz, et al., 1990a; Goetz, et al., 1990b; Jenkins, 1991), reduce the severity of 
pulmonary cardiovascular effects in a porcine model (Byrne, et al., 1990), enhance resistance to 
pneumonia in cattle and swine (Canning, 199S; Canning, et al., 199S), and reduce pain 
associated with rheumatoid arthritis (Grabowsid, et al., 1996).
The interaction of CIM with the LEUK preparation in Experiment 3 did not result in 
classical CYP Type I or n  difference spectra. However, the spectra were similar to the 
difference spectra of oxidized/unoxidized CYP (Hlavica, et al., 1989). This was apparent for 
all of the compounds evaluated in Experiment 3 except HEX, which produced a difference 
spectra resembling Type I. Inhibitors of nNOS have been shown to produce either Type I or II
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difference spectra using in vitro murine brain preparations (Abu-Soud, et al., 1994). The 
results from Experiment 3 can possibly be explained based on the data from Experiment 4. 
Equine iNOS in the molecular weight region of the 130 IcDa murine iNOS standard (monomer) 
was not detected by Western blot analysis. Western blot analysis, however, did detect proteins 
that had smaller molecular weights. Protection against iNOS protein degradation with protease 
inhibitors did not alter this pattern. The difference spectra preparations (made in the absence of 
protease inhibitors), could have resulted from the binding of the test compounds to fragments of 
equine iNOS, such as those that were detected by the Western blots, thus resulting in atypical 
difference spectra. The resulting difference spectra indicate that the test compounds were 
possibly interacting with protein fragments, but did not produce classic Type I or II spectra as 
was seen in the hepatic microsomal preparations.
It could also be hypothesized that the proteins detected in Experiment 4 were other 
isoforms of NOS, such as equine eNOS. This isoform o f NOS has been shown to be up- 
regulated during cirrhosis in parallel to increases in TNF-a and NOx'  concentrations in rats 
following bile duct ligation (Liu, et al., 1999). It is also possible that the proteins detected 
using this murine iNOS antibody are a result of non-specific binding to the iNOS antibody.
Cimetidine does not interact with all heme-containing proteins. It has been shown, for 
example, that it does not form a 6 ® axial ligand on heme-iron of mouse catalase (Baird, et al., 
1987). It was possible that one of the detected proteins in Experiment 4 was equine Hb, but 
upon additional Western blot analysis, this was proven not to be the case. The results from 
Experiment 6  indicate that at a concentration of 1.0 mM, CIM interacted via an unknown 
mechanism to alter the absorbance spectrum of equine Hb. This alteration in the spectrum may 
have been the result of binding to the heme-iron, but is not clear based on the current results.
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The results o f Experiment 6  also suggest that CIM did not affect die metabolism of NO to N 03~ 
catalyzed by Hb. The pathways of NO metabolism are shown in Figure 4.2S below.
NO.
Hb +
Figare 425. Pathways of Nitric Oxide (NO) metabolism.
Cimetidine produced difference spectra that suggests an interaction with CYP, LEUK, 
and Hb in these experiments. These are not definitive studies as the presence o f iNOS could not 
be confirmed following inflammatory stimulus in the horse, as in Simmons, et al. (1999a). 
Simmons’ work used human recombinant IL -ip to induce a localized synovial inflammation in 
the horse. It stimulates the production o f NO and PGE2 in a concentration dependent manner 
(Attur, et al., 1998; Jlrvinen, et al., 1996; Lu & Fiscus, 1999). In the horse, this model 
produces an increase in leukocyte infiltration following intra-articular administration (Simmons, 
et al., 1999a) similar to the infiltration seen in the study reported in Chapter 3. Inducible NOS 
activity could not be detected by measuring the conversion of radiolabeled L-Arg to L-citrulline 
in Simmons’ study (1999a). This could be due to the technique which was employed to isolate 
iNOS, or that iNOS was not induced in their model of equine inflammation.
The need for continued research in the area of equine iNOS was made evident by the 
results of die above studies. The direction o f future efforts could take several different avenues. 
One area o f investigation would be to focus on different inflammatory models. The use of LPS 
to induce a localized inflammation in fleshly chambered horses would be one approach. 
Lipopotysaccharide is a well established agent for the induction of inflammation (Fusder, et al.,
106
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
1997) and of iNOS (Curran, et al., 1989; Fusder, et al., 1997; Pendino, et al., 1993). This 
inflammatory agent may be better suited to iNOS induction in the horse than carrageenan. 
However, LPS did not produce significant changes in plasma NO3'  in the equine following a 35 
ng/kg IV infusion o f LPS over a 30 min period. This model did produce significant decreases 
in urinary NO3'  at 4 and 24 h post-LPS (Bueno, et al., 1999).
Another approach would be to culture equine leukocytes and stimulate them with an 
inflammatory agent, such as LPS or carrageenan. The advantage with these experiments would 
be the possible decrease in degradation of proteins, which may have been an issue in the above 
experiments. Isolation and purification of equine iNOS could be done in cultured leukocytes 
following confirmation o f iNOS production via Western blot analysis. The isolated iNOS could 
then be used for difference spectra analysis and enzyme kinetic studies.
It is unclear whether the NO3* detected in the TCF and plasma following carrageenan 
administration was o f iNOS or CYP origin. It is possible that the concentration of the various 
cytokines produced by the carrageenan model in vivo were sufficient to induce hepatic CYP 
proteins to produce N O . In vitro experiments centered on the production of N O  and/or N O f in 
equine hepatocytes could thus prove useful. The expression o f equine iNOS and various CYP 
isoforms in hepatocytes could be determined using Western blot analysis. Experiments 
involving dexamethasone, which inhibits the de novo synthesis of iNOS (Di Rosa, et al., 1996; 
Fukuto & Chaudhuri, 1995; Radomsld, et al., 1990; Radomski, et al., 1993) would also be 
important This mechanism of inhibition is controlled by a specific ligand/receptor interaction 
which occurs at therapeutic concentrations of dexamethasone and is highly correlated with its 
anti-inflammatory efiect Dexamethasone is also a proven inducer of CYP, especially the 3A 
isoform (MaureL, 1996). Dexamethasone may be useful in separating the contribution o f iNOS
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and CYP to NO production. Carrageenan or LPS could be used to simulate the inflammatory 
disease state in these cultured cells.
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CHAPTER 5. SUMMARY CONCLUSIONS 
It is clear from these studies, and others, that carrageenan stimulates the production of 
NO (Ianaro, et al., 1994; Koga, et al., 1995; Salvemini, et al., 1995; Tracey, et al., 1995). The 
above referenced reports also suggest that the increase in NO production can be attributed to 
the infiltration o f leukocytes, mainly neutrophils and tissue macrophages, that subsequently 
become activated at the inflammatory site, resulting in an increase in NO production. Adler, 
et al., (1996) reported that activated macrophages are those in which iNOS has been induced 
and production o f NO within the cell has increased. Cytokines can be formed as part of an 
inflammatory response and start a pro-inflammatory cascade, which stimulates the production 
of NO (Ianaro, et al., 1994). This production of NO could be due to induction of iNOS or 
CYP proteins, but CYP isoforms are typically repressed as a result of inflammation, not 
induced (Mauler, 1996). Curran and coworkers (1989) reported, using cultured rat 
hepatocytes and Kupffer cells, that following the induction of inflammation (LPS), NOf/NOs' 
production increases and protein synthesis decreases. This appears to be a synergistic 
mechanism between hepatocytes and Kupffer cells, in that when Kupffer cells and hepatocytes 
were cultured separately these changes were only observed in the Kupffer cells.
The NO produced in response to carrageenan is attributed mainly to neutrophils and 
macrophages (Ianaro, et al., 1994; Koga, et al., 1995; Salvemini, et al., 1995; Tracey, et al., 
1995). In all of these studies, the production o f NO or the induction of iNOS mRNA reached 
maximum levels at 12 h post stimulation. One study that employed immunohistochemical 
staining for iNOS, showed that most of the activity was associated with tissue macrophages 
(Salvemini, et al., 1995). In Trial 1, the increase in NO3'  production paralleled the influx of 
neutrophils into the chamber (Tables 3.2 & 3.3).
Inducible NOS contains both a CYP and a reductase domain within a single 
polypeptide, thus having the properties o f both and allowing for electron transfer from
109
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
NADPH to the heme-iron protein within one enzyme (Guengerich, 1996). The 3A subfamily 
of CYP can convert L-Arg to L-citrulline and N O  (Andronik-Lion, et al., 1992; Boucher, et al., 
1992; Schott, et al., 1994). It is not unexpected that CIM, which antagonizes CYP activity by 
binding to the heme-iron containing catalytic site (Kuo, et al., 1995), could also inhibit the 
activity of iNOS, an enzyme with a similar active site. Therefore, it was logical to expect that 
NO derived NO3' concentrations in TCF and plasma could be reduced by CIM.
In the absence o f O2, NO dissolves in H2O and is very stable. In air it will react with 
0 2 to form N 02. In H2O and plasma, NO is oxidized to NO2 , which is stable for several 
hours. In whole blood, N 02' and, to a much greater extent NO, are rapidly converted to NO3' 
via a Hb catalyzed oxidation (Doyle A  Hoekstra, 1981; Moncada A  Higgs, 1993; Wennmalm, 
et al., 1992). As little as 0.2 mM Hb (4% of normal blood concentration) essentially 
eliminates the presence of NO in arterial blood (Henry A  SingeL, 1996; Lancaster, 1997) in <2 
sec with ONOO* and/or nitrosyl Hb serving as a possible intermediates (Doyle A  Hoekstra, 
1981; Henry A  SingeL, 1996).
Both CIM and AG treatment resulted in a failure o f N 03' concentrations to rise 
significantly in plasma or test chamber between 4 and 12 h post-carrageenan instillation. 
Additionally, the plasma concentrations were similar to TCF concentrations at each o f the 
three time points, even though the values at 12  h were substantially lower than for either 
chamber during NaCl treatment This supports the above interpretation that NO, measured as 
NO3", equilibrates fairly rapidly between vascular and non-vascular compartments.
The presence o f membrane bound p recep to rs on leukocytes has been previously 
reported (Tasaka, et al., 1992; Vannier, et al., 1991). It is possible that iNOS could be 
coupled to membrane bound p recep to rs on leukocytes, similar to the mechanism by which 
IL-6  synthesis and receptor expression is altered by HIS (Merdtey, et al., 1991; Vannier A  
Dinarello, 1994) or in which HIS increases IL -lp mRNA levels (Vannier A  Dinarello, 1993).
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If NO production were regulated by an Hrreceptor mechanism, then administration of HIS 
would cause an increase in NO production or iNOS mRNA synthesis. Histamine regulates the 
formation of many pro-inflammatory mediators (Auer, et al., 1991; Rezai, et al., 1990; 
Vannier, et al., 1991), so it would not be surprising if it had a role in regulating NO production 
(Kelm, et al., 1993; Mannaioni, et al., 1997).
There is no documented interaction of either L-Arg or AG with Hrreceptors. It is 
possible, however, to hypothesize that since CIM binds to these receptors (Brimblecombe, et 
al., 1978), similar guanidine-like compounds such as AG could also interact If so, then it 
could also be possible for AG or CIM to be internalized through interaction with the receptor, 
allowing for transport o f the compound across the membrane and into the cytosolic space, 
where it could interact with iNOS.
It is possible that the lack o f a parallel reduction of TNF-a, IL-1, & IL-6  production 
with N 0 3' prior to day 3 of the study was due to the regulation o f iNOS or CYP proteins. For 
induction o f these enzymes, pro-inflammatory cytokines must first be produced. Once this 
takes place and results in increased NO production, the resuiting increase in NO causes a 
positive feedback to increase TNF-a, IL-1, & IL-6  production. Even with CIM and AG 
pretreatment, the resulting decrease in NO production appears to be too late to decrease the 
early cytokine response. However, it may assist in preventing the NO-induced up-regulation 
of pro-inflammatory cytokine production.
The expected result of CIM treatment decreasing IL-1 and IL-6  production (Vannier 
& Dinarello, 1993; Vannier & Dinarello, 1994) was not observed in the study reported in 
Chapter 3. There was no significant difference between the AUCs of IL-1 or IL-6  in NaCl-N 
TCF vs. CIM TCF. Also, CIM treatment did not affect values obtained for the inflamed TCF. 
It is possible that this is a result o f the dosage regimen used in Trial 1. This could have
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resulted in sub-efficacious concentrations of CIM present in TCF and the inability o f CIM to 
inhibit IL-1 and IL-6  production to a level that would be statistically significant.
Nitric oxide synthase is the first catalytically self-sufficient CYP to be described 
(White & Marietta, 1992). It has been suggested that AG, a competitive antagonist o f iNOS, 
acts through interaction of the guanidine N with the heme-iron of the porphyrin ring (Griffith 
& Gross, 1996; Griffiths, et al., 1993; White & Marietta, 1992). This is probably not the case, 
at least for CYP, since AG produced a Type I difference spectra in both rat and equine hepatic 
microsomes. Type I difference spectra are the result o f alteration of heme absorption by 
increasing the polarity o f the 6 th (axial) heme ligand without having direct interaction with the 
heme (Schenkman, et al., 1973). The active she for the binding of CIM to CYP is also the 
heme-iron moiety of the latter (Ioannoni, et al., 1986; Rendid, et al., 1984). The Cys 184 
residue in human eNOS, Cys 415 in rat nNOS, and Cys 194 for murine iNOS appear to be the 
proximal heme ligands for L-Arg binding in the various isozymes (Chen, et al., 1994; 
McMillan & Masters, 1995). The guanidino N and the guanidino C of L-Arg must be in close 
proximity to the heme-binding ligand (Griffith & Stuehr, 1995).
The heme found in NOS, located in the NHz-terminal domain, is necessary for the 
conversion of L-OHArg to NO and L-chrulline since L-OHArg appears to bind in the 
proximity of the heme and alters the spin state of Fe upon binding. This results in a Type I 
spectra and is similar to the spectra obtained from CYP after binding of substrates and 
suggests that L-Arg is altering the heme microenvironment o f NOS (Kerwin, et al., 1995). 
This was not seen with L-Arg in the rat hepatic microsome preparation used in Experiment 1, 
but HEX and AG did produce this type of spectra in both species of hepatic microsome 
preparations. Aminoguanidine is probably interacting with CYP via the guanidine moiety 
common to both L-Arg and AG. It is unclear if the binding sites for L-Arg and L-OHArg are 
the same (Pufahl & Marietta, 1993), but this has been suggested (Kerwin, et al., 1995).
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Cimctidine is a proven inhibitor of CYP while ZAL is suspected of this activity 
(Farup, et al., 1988; Ioannoni, et al., 1986; Rendil, et al., 1984). Farup, et al. (1988) mention 
that this effect is also observed after IV administration of RAN. Ranitidine did not produce a 
Type II difference spectra in either rat or equine hepatic microsome experiments. The 
inhibition of CYP is mediated through the heme containing protein binding to structurally 
similar H2-antagonists as a 6 th axial ligand with Fe (Rendil, et al., 1983). This binding results 
in a Type II difference spectrum (Lin & Lu, 1998; Schenk man, et al., 1967) associated with 
the direct binding of CIM to the heme moiety and the formation o f a ferrihemochrome 
(Schenkman, et al., 1973). This was reproduced using rat and equine hepatic microsomes in 
Experiments 1 and 2 of Chapter 4 and is consistent with results previously reported (Rendic, et 
al., 1983; Rendid, et al., 1984).
The Type II difference spectra o f HIS in the hepatic microsomes o f both species is 
produced through the interaction o f the imidazole group binding as a 6 * axial ligand (Brandes, 
et al., 1998). This interaction o f HIS with CYP isoforms is believed to also involve an 
intracellular HIS receptor located on or near the nuclei and chromatin of hepatocytes. These 
HIS receptors appear to regulate the catalytic activity of CYP and also modulate the growth of 
normal and neoplastic cells (Brandes, et al., 1998). This may be one mechanism to explain 
the anti-tumor, anti-infective, and either pro- or anti-inflammatory properties of Hy- 
antagonists. Cimetidine and other p re c e p to r antagonists have been shown to reduce the size 
of equine melanomas (Goetz, et al., 1990a; Goetz, et al., 1990b; Jenkins, 1991), reduce the 
severity o f pulmonary cardiovascular effects in a porcine model (Byrne, et al., 1990), enhance 
resistance to pneumonia in cattle and swine (Canning, 199S; Canning, et al., 1995X and reduce 
pain associated with rheumatoid arthritis (Grabowski, et al., 1996).
The interaction of CIM with the LEUK preparation in Experiment 3 did not result in 
classical Type I or II difference spectra. It is very possible that this is due to the fact that
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iNOS, if it existed in the chamber leukocytes, was degraded and therefore lost its complete 
tertiary structure. However, the spectrum produced by CIM with LEUK was similar to the 
difference spectra o f oxidized/unoxidized CYP (Hlavica, et al., 1989). This was apparent for 
all o f the compounds evaluated in Experiment 3 except for HEX, which yielded a difference 
spectra resembling Type I. Inhibitors o f nNOS have been shown to produce either Type I or II 
difference spectra using in vitro murine brain preparations (Abu-Soud, et al., 1994).
Equine iNOS in the molecular weight region o f the 130 kOa murine iNOS standard 
(monomer) was not detected in the LEUK preparations by Western blot analysis. Western 
blot analysis, however, did detect proteins that had smaller molecular weights. Protection 
against iNOS protein degradation with protease inhibitors did not alter this pattern. This could 
have been due to the fact that the protease inhibitors could not be added until * 2  h after 
removal of the TCF. The difference spectra preparations (made in the absence of protease 
inhibitors), could have resulted from the binding o f the test compounds to fragments of equine 
iNOS, such as those that were detected by the Western blots, thus resulting in non-classical 
difference spectra. The resulting difference spectra indicate that the test compounds interacted 
with a chromogenic ferrihemochrome protein fragments), but did not produce classic Type I 
or II spectra as was seen in hepatic microsomal preparations.
Cimetidine does not interact with all heme-containing proteins. It has been shown, for 
example, that it does not form a 6* axial ligand on heme-iron of mouse catalase (Baird, et al., 
1987). It was possible that one of the detected proteins in Experiment 4 was equine Hb, but 
Western blot analysis provided evidence that this was not the case. The results from 
Experiment 6  indicate that at a concentration o f 1.0 mM, CIM interacted via an unknown 
mechanism to alter the absorbance of equine Hb. This may have been through binding to the 
heme-iron, but was not clear. At a Hb concentration of *0.001 mM, which is approximately
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that of the concentration in the LEUK preparation, CIM did not alter the binding spectra o f
Hb.
Cimetidine produced difference spectra that suggest it was interacting with CYP, 
LEUK, and Hb (1.0 mM CIM) in these experiments. These are not definitive studies as the 
presence o f iNOS could not be confirmed following inflammatory stimulus in the horse, as in 
Simmons, et al. (1999a). In that study, Simmons and coworkers used human IL-lp to induce 
an inflammatory response in equine synovial joints. The fluid removed from these joints 
showed a moderate inflammatory response with increases in IL -ip  and IL-6 . The activity o f 
NOS was measured using the conversion of L-[uC]Arg to L-[uC]citrulline. There was no 
significant difference in NOS activity between healthy and inflamed joints. The presence o f 
equine iNOS could also not be determined in vitro, using cultured equine monocytes exposed 
to LPS (Drs. Rustin Moore & David Horohov, personal communication). This is in contrast to 
results reported in equine alveolar macrophages where both iNOS and COX-2 mRNA were 
induced in vitro following exposure to endotoxin (Hammond, et al., 1999). The results also 
suggest that CIM did not affect the metabolism of NO to NO3'. It may not be possible to 
isolate intact iNOS from the type o f chamber used in these studies. It seems apparent that 
stimulation of inflammation with carrageenan in these chambers results in degradation o f 
iNOS, so that only small molecular weight fragments that bind with murine iNOS antibody 
are recoverable. This is even the case with unstimuiated chambers, which probably reflects a 
low grade inflammatory process resulting from the high frequency o f use o f the chambers in 
these later studies. The ability o f CIM to reduce circulating NOT concentrations through 
inhibition of NO generation by iNOS or CYP remains to be proven.
The need for future research in this area is evident. The scope o f these efforts could 
take several different directions. The first step would be to determine if  iNOS is present in 
equine leukocytes. If it is, then efforts to purify and isolate it for enzyme inhibition studies
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would be warranted. If iNOS cannot be isolated from equine leukocytes in vitro, then it is 
possible that a CYP isoform(s) was responsible for the N 03‘ observed following carrageenan 
administration. Western blot analysis could be done with equine leukocytes using a 
polyclonal or monoclonal antibody for CYP.
Another avenue o f investigation would be to focus on different inflammatory models. 
The use o f LPS to induce a localized inflammation in freshly chambered horses would be one 
approach. Lipopolysaccharide is a well established agent for the induction of inflammation 
(Fuseler, et al., 1997) and of iNOS (Curran, et al., 1989; Fuseler, et al., 1997; Pendino, et al., 
1993). This inflammatory agent may be better suited to iNOS induction than carrageenan, but 
it did not produce changes in plasma NO3'  concentrations in the equine following a 30 min IV 
infusion of a low dose o f 35 ng/kg LPS (Bueno, et al., 1999). This may contradict the 
findings o f Hammond, et al., (1999) who detected iNOS mRNA following stimulation with 
LPS in vitro. Another approach would be to culture equine leukocytes and stimulate them 
with LPS. The advantage of this approach is that it could result in a decrease in extraneous 
material that could be interfering with the Western blot analysis. Isolation and purification of 
equine iNOS could be accomplished following confirmation o f its presence (Western blot). 
The isolated iNOS could be used for difference spectra analysis and enzyme kinetic studies. It 
should be noted, however, that iNOS was not detected in vitro using LPS stimulated equine 
monocytes followed by immunohistochemical staining. This method used a murine iNOS 
primary antibody, the same one used in the Western blots reported in Chapter 4, and an 
avidin-biotin complex for detection (Dr. Rustin Moore, personal communication).
In order to show that CIM could directly alter iNOS activity, established models of 
carrageenan and LPS induced inflammation in rodents would be used (Enna, et al., 1999) and 
iNOS isolated. The isolated iNOS enzyme could then be used for difference spectra and 
enzyme inhibition studies with CIM. The presence o f iNOS could also be confirmed using a
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commercial antibody for detection of murine iNOS. This would allow confirmation of the 
theories expressed in this manuscript, but would not determine the exact mechanism o f CIM 
reduction o f NO3* concentrations in the equine due to possible species differences in iNOS 
expression and structure.
To determine if CYP has a role in the production of N 03' following an inflammatory 
stimulus, use of cultured equine hepatocytes would be a useful technique. Based on the 
experiments conducted to date, it was unclear whether the N 03‘ detected in the TCF and 
plasma following carrageenan administration was of iNOS or CYP origin. It was possible that 
the concentration o f the various cytokines produced in vivo were sufficient to induce hepatic 
CYP proteins to produce NO. In vitro experiments centered on the production of NO and/or 
N 03' in equine hepatocytes could thus prove useful. The expression of equine iNOS and 
various CYP isoforms in hepatocytes could be determined using Western blot analysis. 
Experiments involving dexamethasone, which inhibits the de novo synthesis of iNOS (Di 
Rosa, et al., 1996; Fukuto & Chaudhuri, 1995; Radomski, et al., 1990; Radomski, et al., 1993) 
would also be important. This mechanism of inhibition is controlled by a specific 
ligand/receptor interaction which occurs at therapeutic concentrations of dexamethasone and 
is highly correlated with its anti-inflammatory effect. Dexamethasone is also a proven inducer 
of CYP, especially the 3A isoform (Maurel, 1996). Dexamethasone may be useful in 
separating the contribution of iNOS and CYP to NO production. As mentioned above, various 
inducers of inflammation could be used to simulate the inflammatory disease state in these 
cultured cells.
In conclusion, CIM, an H2-receptor antagonist used to treat and prevent gastric 
ulceration, is effective in reducing inflammation-generated NO3" concentrations. This could 
occur via inhibition o f iN O S by the same mechanism o f heme-iron binding that CIM employs 
to inhibit CYP mediated metabolism. It is also possible that the cytokines produced in this
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carrageenan model for inflammation induced CYP expression, resulting in an increase in N 03' 
concentrations and that CIM inhibited CYP and not iNOS. The effect could also be attributed 
to an interaction at Hrreceptors on leukocytes or macrophages. These finding bring focus to; 
1) the potential effect of similar H2-receptor antagonists on inflammation related NO 
production; 2 ) the possibility that other guanidine moiety containing substances may affect 
NO production, and 3) the question o f whether CIM or other Hz-receptor antagonists inhibit 
constitutive NOS isoforms and therefore affect physiologic processes other than inflammation.
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